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ABSTRACT 
 
This study investigated the phytochemical constituents, primarily gallotannins, 
present in a proprietary extract, namely Maplifa
TM
, from leaves of the red maple (Acer 
rubrum L.) species as well as their biological activities and mechanisms of action.  
Although the red maple species has been traditionally used as folk medicine by Native 
American Indians for numerous health benefits, the bioactive chemical constituents of the 
leaves of the red maple still remain unknown.  This study carried out the identification of 
phytochemicals targeting gallotannins, a class of polyphenols, from red maple leaves by 
using various chromatographic separation techniques and spectroscopic approaches.  
Furthermore, compounds from the red maple species were evaluated for bioactivities 
including anti-oxidant, anti-diabetic (α-glucosidase enzyme inhibition and inhibition of 
advanced glycation end products, AGEs) and skin lightening effects (anti-tyrosinase and 
anti-melanogenesis) by using a panel of in-house bioassays.  In addition, the mechanisms 
of the inhibitory effects of red maple phytochemicals on α-glucosidase were 
characterized by using kinetic assay, fluorescence assay, FTIR and CD (circular 
dichroism) spectra.  Moreover, the mechanisms of inhibition of the gallotannins on the 
formation of AGEs were elucidated at each individual stage of AGEs formation by 
applying MALDI-TOF mass spectroscopy, HPLC-FL analysis, G.K. peptide assays, and 
assessing the conformational changes induced by protein glycation by using CD. 
Plant derived natural products have served as an important resource for medicinal 
compounds over decades.  The red maple is an indigenous plant species of eastern North 
America and was extensively used as an herbal remedy by the indigenous peoples of 
  
 
 
eastern North American region for many ailments including abdominal pain, diarrhea and 
eyes diseases.  
Recent studies have shown that extracts of red maple plant parts exhibit free 
radical scavenging capacities and this antioxidant property was associated with its 
polyphenolic content.  Red maple extracts have also been investigated for their 
antimicrobial and anticancer effects.  In addition, our group has recently demonstrated 
that a red maple bark extract was able to decrease blood glucose levels in mice after 
sucrose loading indicating the presence of bioactive compounds that could be relevant to 
diabetes management.  Furthermore, our laboratory has recently isolated a number of new 
gallotannins, named maplexins A-I, from the stem and bark of the red maple species and 
has shown that these compounds display potent α-glucosidase inhibitory activity in vitro.  
As the total polyphenolic content level in red maple leaves is higher than in bark, it is 
logical to investigate the chemical constituents of red maple leaves for gallotannins which 
could also serve as α-glucosidase inhibitors.  Therefore, we propose a phytochemical 
study to develop a proprietary extract from red maple leaves and to isolate and identify 
phenolic compounds therein and evaluate these compounds for their in vitro antioxidant 
and anti-diabetic activities.  This study also proposes to elucidate the mechanisms of 
inhibitory effects of maple gallotannins on the α-glucosidase enzyme by using various 
biophysical tools.  Understanding the mechanisms of inhibitory action of these 
compounds will be critical for the further development of α-glucosidase inhibitors from 
maple for diabetes management.   
Beside the inhibitory effects on the α-glucosidase enzyme, the red maple 
gallotannins were also evaluated for their inhibitory effects on the formation of advanced 
  
 
 
glycation end products (AGEs), another therapeutic target of diabetes.  AGEs are a 
heterogeneous group of irreversible adducts from non-enzymatic glucose-protein 
condensation reactions.  It has been reported that AGEs as oxidative derivatives are 
increasingly being implicated as a potential risk for diabetes.  Numerous studies have 
demonstrated that phenolics with anti-oxidative capacity from fruits or vegetables could 
effectively interrupt the condensation reaction of glucose and proteins and further 
decrease the formation of AGEs.  Therefore, we hypothesize that gallotannins from red 
maple species might act as antioxidants and inhibit the formation of AGEs. 
In addition to anti-diabetic activities, the skin lightening effects of red maple 
gallotannins, as a treatment strategy for hyperpigmentary disorders, were also evaluated 
in this study.  Hyperpigmentary disorders, such as melasma, age spot, freckles and 
lentigies, are caused by the accumulation of abnormal melanin.  In the melanin 
biosynthetic pathway, tyrosinase is an exclusive enzyme responsible for the formation of 
melanins.  Emerging data suggests that several plant-derived constituents may act as 
natural tyrosinase inhibitors which are of interest to the food (as anti-browning agents) 
and cosmetic (as skin lightening agents) industries.  Therefore, we also evaluated the 
anti-tyrosinase and anti-melanogenic properties of gallotannins isolated from red maple 
leaves. 
 
In Manuscript I:  the objective was to develop a proprietary standardized red maple leaf 
extract, named Maplifa
TM
, for potential nutraceutical and/or cosmeceutical applications.  
In addition, the total phenolic content of Maplifa
TM
, was determined as gallic acid 
equivalents (GAEs) and the major gallotannins present in Maplifa
TM
 were identified as 
  
 
 
maplexin B, ginnalin B, ginnalin C, ginnalin A, maplexin F and a pair of isomers, 6-O-
digalloyl-2-O-galloyl-1,5-anhydro-D-glucitol and 2-O-digalloyl-6-O-galloyl-1,5-anhydro-
D-glucitol.  The quantitative HPLC-UV analysis revealed that ginnalin A was the 
predominant gallotannin in Maplifa
TM
 (56.3% by dried weight).  Furthermore, Maplifa
TM
 
was evaluated for various bioactivities including anti-oxidant, anti-tyrosinase, anti-α-
glucosidase and anti-AGEs.  Maplifa
TM
 showed potent anti-oxidant activity in the DPPH 
assay with an IC50 of 78.2 ppm.  Also, Maplifa
TM
 showed inhibitory effects on the 
tyrosinase and α-glucosidase enzymes (IC50 = 154.5 ppm and 37.8 ppm, respectively).  
Lastly, Maplifa
TM
 displayed inhibitory activity against the formation of AGEs (IC50 = 8.6 
ppm), which was 10-fold more potent than aminoguanidine as the positive control.  
Findings from this study suggest that Maplifa
TM
 could have potential cosmetic (for e.g. 
skin-whitening/lightening) and/or nutraceutical (for e.g. anti-diabetic) applications but 
further in vivo studies would be required to confirm this. 
 
In Manuscript II, as our previous phytochemical studies on red maple (Acer rubrum) 
species lead to the identification of a series of maple gallotannins as potent α-glucosidase 
inhibitors, we aimed to provide insights into the ligand-enzyme interactions and the 
binding mechanisms of the maple gallotannins and the α-glucosidase enzyme.  The 
inhibitory effects of four gallotannins from red maple species, namely ginnalin A, 
ginnalin B, ginnalin C and maplexin F, as well as a synthetic derived gallotannin, namely 
maplexin J, were evaluated against α-glucosidase.  The inhibitory effects of the 
gallotannins against the α-glucosidase enzyme were determined as a noncompetitive 
mode.   The interactions between the gallotannins and α-glucosidase were further 
  
 
 
elucidated by using spectroscopic means. The results revealed that the gallotannins 
inhibited α-glucosidase by forming stable ligand-enzyme complexes which consequently 
lead to the quenching of their intrinsic fluorescence statically.  In addition, a fluorescent 
probe 1,1′-bis(4-anilino-5-napththalenesulfonic acid (bis-ANS), was used to explore the 
binding regions of the  gallotannins.  Lastly, FTIR and CD data showed that the 
gallotannins bound to α-glucosidase and induced conformational changes to the enzyme.  
These findings were further discussed in the context of structure activity relationship 
(SAR) for the potential of developing structural gallotannin analogs as potent α-
glucosidase inhibitors. 
 
In Manuscript III, the objective of this study was to evaluate the inhibitory effects of a 
series of maple gallotannins, namely ginnalins A-C and maplexins F and J, at individual 
stage of protein glycation using a combination of analytical methods including 
fluorescence spectroscopy, HPLC-FL, CD, and MALDI-TOF. Both early and middle 
stages of protein glycation inhibition by the maple gallotannins was determined by using 
the BSA-fructose assay. In this assay, maplexin F showed the most potent inhibitory 
effect against the formation of AGEs with an IC50 value of 15.8 µM.  In addition, 
MALDI-TOF analysis revealed that the maple gallotannins were able to reduce the 
number of fructose that adducted to BSA protein indicating that they were able to inhibit 
the production of Amadori products. Moreover, the maple gallotannins were effective in 
the G.K. peptide-ribose assay suggested that the protein cross-linking formation at the 
late stage of glycation could be prevented by maple gallotannins.  Lastly, the 
  
 
 
spectroscopy analyses revealed that the maple gallotannins were able to reduce the 
conformational changes of BSA protein that were induced by glycation. 
 
In MANUSCRIPT IV, we initiated a project to investigate the cosmetic skin 
lightening/whitening applications of Maplifa
TM
, a proprietary extract purified from the 
leaves of the red maple species, in enzyme and cell based assays.  Maplifa
TM
 is 
standardized to ca. 45-50% of ginnalin A along with other gallotannins including ginnalin 
B and C and maplexins.  SAR studies showed that increasing the number of galloyl 
groups attached to the 1,5-anhydro-D-glucitol moiety resulted in greater  inhibitory 
effects on the tyrosinase enzyme. Consequently we synthesized maplexin J, a 
tetragalloyl-glucitol (contains the maximum number of 4 galloyl groups on the1,5-
anhydro-D-glucitol core) and confirmed our SAR observations.  Purified ginnalins A-C, 
as representative gallotannins in Maplifa
TM
, were assayed for their inhibitory effects on 
melanin production in murine B16F10 cells.  Ginnalin A (contains 2 galloyl groups) 
clearly reduced the melanin content at 50 μM whereas ginnalin B and C (contain 1 
galloyl group of each) showed only minor anti-melanogenic effects.  Lastly, the 
mechanisms of the inhibitory effects of ginnalins A-C on melanogenesis in B16F10 cells 
were elucidated by using real-time PCR and Western blot experiments.  The results 
indicated that ginnalins were able to down-regulate the expression of MITF, TYR, TRP-1 
and TRP-2 gene levels in a time and dose-dependent manner and significantly reduce the 
protein expression of TRP-2 gene.  The findings in our study indicate that 
phytochemicals in red maple leaves possess anti-melanogenic effects and thus may have 
potential cosmetic skin-whitening applications. 
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ABSTRACT 
 Our previous studies revealed that extracts of maple (Acer) species possess 
numerous biological activities attributed to their polyphenolic contents.  In order to 
utilize maple extracts for potential nutraceutical and cosmeceutical applications, we 
developed a proprietary maple extract, namely Maplifa
TM
, from red maple (Acer rubrum 
L.) leaves.  In addition, the total phenolic contents of Maplifa
TM
 were determined in 
tgallic acid equivalents (GAEs) and the major polyphenols present in Maplifa
TM
 were 
identified as maplexin B (1), ginnalin B (2), ginnalin C (3), ginnalin A (4), maplexin F 
(5) and two isomers (6a and 6b), 6-O-digalloyl-2-O-galloyl-1,5-anhydro-D-glucitol (6a) 
and 2-O-digalloyl-6-O-galloyl-1,5-anhydro-D-glucitol (6b).  Quantitative HPLC-UV 
analysis revealed that ginnalin A was the predominant phenolic in Maplifa
TM
 (56.3% of 
dried weight).  Furthermore, Maplifa
TM
 was evaluated for various bioactivities including 
anti-oxidant, anti-tyrosinase, anti-α-glucosidase and anti-AGEs.  MaplifaTM showed 
potent anti-oxidant activity in the DPPH assay with an IC50 of 78.2 ppm.  Also Maplifa
TM
 
showed inhibitory effects on tyrosinase and α-glucosidase (IC50 = 154.5 ppm and 37.8 
ppm, respectively) enzymes.  Lastly, Maplifa
TM
 displayed the inhibitory activity against 
the formation of advanced glycation end products, AGEs (IC50 = 8.6 ppm), which was 
10-fold more potent than aminoguanidine, the positive control.  Findings from this study 
suggest that Maplifa
TM
 could have potential cosmetic (for e.g. skin-whitening/lightening) 
and/or nutraceutical (for e.g. anti-diabetic) applications but further in vivo studies would 
be required to confirm this. 
  Keywords: Acer rubrum, red maple, proprietary extract, total phenolic contents, 
gallotannins, anti-oxidant, anti-tyrosinase, anti-diabetes 
  
 
3 
 
INTRODUCTION  
Plants based natural product extracts have been intensively studied for numerous 
biological and pharmacological properties (1, 2).  Apart from playing an important role as 
resources of leading compounds for drug discovery, plants are also considered as 
preferable substances for the nutraceutical and/or cosmeceutical uses since they tend to 
be safer than synthetic agents (3).  It has been demonstrated that many bioactive 
phytochemicals in plant extracts such as phenolic compounds, alkaloids and sterols are of 
great value in human health and beauty applications. 
 Maple (Acer) species, especially the sugar maple (Acer saccharum L.) and red 
maple (Acer rubrum L.), are widely regarded for their sap which is used for the 
production of maple syrup, a natural sweetener.  These maple species have been 
traditionally used by the indigenous peoples of eastern North America as a folk medicine 
for skin and digestive disorders (4).  Recently, maple extracts have attracted research 
interests for their biological activities including anti-oxidant, antibacterial, anti-cancer 
and anti-depressant effects (5-7).  In our own phytochemical and biological investigations 
of various plant parts of the sugar maple and red maple species, our group has isolated a 
series of gallotannins with anti-oxidant, anti-cancer and anti-α-glucosidase activities (8-
11).  It was notable that the gallotannin, ginnalin A, which is the most abundant phenolic 
compound present in the red maple species, displayed potent free radical scavenging 
capacity and anti-proliferative effects in vitro.  Meanwhile, a new gallotannin isolated 
from red maple bark, namely maplexin F, was 20 times more active than acarbose (a 
clinical α-glucosidase inhibitor) in the anti-α-glucosidase assay. Furthermore, our group 
has shown that a red maple bark extract was able to reduce blood glucose level after 
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carbohydrate challenge in an animal model (12).  Therefore, we hypothesized that red 
maple extracts could have potential nutraceutical application for diabetes management. 
 The formation of advanced glycation endproducts (AGEs) is often associated with 
diabetes patients in the hyperglycemic condition and it triggers the generation of 
oxidative stress which further leads to numerous diabetic complications including kidney 
failure, cardiovascular diseases and atherosclerosis (13, 14).  Therefore, plants extracts 
with inhibitory effects against AGEs formation could be a therapeutic strategy for related 
diabetic complications. 
 Plants extracts with free radical trapping capacity have been desired as 
alternatives of skin whitening agents (15).  Tyrosinase is a rate-limiting oxidase that 
converts a monophenol to o-quinone and then catalyzes a set of reactions that eventually 
produce melanin as skin pigments (16).  Thus, tyrosinase inhibitors, in particular from 
natural sources, are highly sought as skin whitening agents for the cosmeceutical 
industry. 
 Due to the aforementioned biological bioactivities of maple extracts and their 
potential applications for the treatments of diabetes and associated complications and for 
cosmeceutical utilization, we initiated this study to develop Maplifa
TM
, as a standardized 
red maple leaves extract.  The total polyphenol content of Maplifa
TM
 were determined in 
gallic acid equivalents (GAEs) and its major phenolics were identified by HPLC-UV 
methods by comparison to authentic standards previously isolated from maple species by 
our laboratory.  Lastly, Maplifa
TM
 were evaluated by using a series of bioassays for its 
nutraceutical and cosmeceutical applications. 
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 MATERIALS AND METHODS  
Chemicals and General Experimental Procedures 
 High performance liquid chromatography (HPLC)-UV was performed on a 
Hitachi Elite LaChrom system consisting of a L2130 pump, L-2200 autosampler and a L-
2455 diode array detector all operated by EZChrom Elite software.  All solvents were 
ACS or HPLC grade and were obtained from Sigma-Aldrich through Wilkem Scientific 
(Pawcatuck, RI, USA). Unless otherwise stated, all reagents including the Folin-
Ciocalteu reagent, gallic acid, ascorbic acid, butylated hydroxytoluene (BHT), 
diphenylpicrylhydrazyl (DPPH) reagent, α-glucosidase (EC 3.2.1.20) from 
Saccharomyces cerevisiae, p-Nitrophenyl-α-D-glucopyranoside (pNPG), aminoguanidine 
(AG), bovine serum albumin (BSA), glucose, mushroom tyrosinase, L-tyrosine, 4-
hydroxyphenyl β-D-glucopyranoside (arbutin) and kojic acid were purchased from 
Sigma-Aldrich (St Louis, MO, USA).  The authentic maple standards in the HPLC-UV 
analysis were previously isolated by our group (17-19). 
Plant Material 
 Leaves of the red maple (Acer rubrum) species were collected on the Kingston 
Campus of the University of Rhode Island (Kingston, RI, USA) in August 2013, and 
identified by Mr. J. Peter Morgan (URI Senior Gardener). Voucher specimens 
(11/6/09LPMCL2) are deposited in the Heber W. Youngken Jr. Medicinal Garden and 
Greenhouse at the College of Pharmacy, University of Rhode Island. 
Extraction of Red Maple Leaves and Preparation of Maplifa
TM
 
 The extraction of red maple leaves and preparation of the proprietary Maplifa
TM
 
extract was according to standardized protocols developed in our laboratory (20).  
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Briefly, dried red maple leaves (100.0 g) were soaked 95 % ethanol (3 x 400 mL) at room 
temperature. The solvent-leaf slurry was allowed to stir for 12 h. The red maple leaves 
extract (RMLE; 50.0 g) was obtained after solvent removal in vacuo. Then RMLE was 
subjected to a column chromatographic method with XAD-16 Amberlite resin as the 
stationary phase.   The RMLE (50.0 g) was absorbed onto the XAD-16 resin column (45 
x 3 cm) and eluted with a water/ethanol solvent system to remove chlorophyll and other 
plant pigments and to yield the Maplifa
TM
 extract (11.4 g) after solvent removal in vacuo.  
Determination of Total Polyphenol Contents of Maplifa
tm
 
 The total phenolic contents of the Maplifa
TM
 were determined according to the 
Folin-Ciocalteu method and were measured as gallic acid equivalents (GAEs) as reported 
previously by our laboratory (20). Briefly, Maplifa
TM
 was diluted 1:100 methanol/H2O 
(1:1, v/v), and 200 μL of sample was incubated with 3 mL of methanol/H2O (1:1, v/v) 
and 200 μL of Folin-Ciocalteu reagent for 10 min at 25 °C. After this, 600 μL of a 20% 
Na2CO3aqueous solution was added to each tube and mixed by vortex. Mixture was 
further incubated for 20 min at 40 °C. After incubation, the samples were immediately 
cooled in an ice bath to room temperature. Samples and standard (gallic acid) were 
processed identically. The absorbance was determined at 755 nm, and final results were 
calculated from the standard curve obtained from a Spectramax plate reader. 
Analytical HPLC-UV Analyses of Maplifa
tm
 
 A Luna C18 column (250 × 4.6 mm i.d., 5 µm; Phenomenex) with a flow rate at 
0.75 mL/min and injection volume of 20 μL for all samples (MaplifaTM and authentic 
standards of compounds 1-7) was used. A gradient solvent system consisting of solvent A 
(0.1% aqueous trifluoroacetic acid) and solvent B (methanol) was used as follows: 0–
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40 min, from 10% to 46% B; 40-60 min, 46–80% B; 65–67 min, 100% B; 67–68 min, 
from 100% to 10% B; 68-75 min, 10% B. Figure 2 shows the HPLC-UV profiles of 
Maplifa
TM
. 
 Identification of Gallotannins Present in Maplifa
tm
 
The major compounds present in Maplifa
TM
 were identified by comparison the 
retention time of HPLC-UV chromatographic profiles of Maplifa
TM
 and authentic 
standards that were previously isolated by our group from the red maple species (10, 11, 
21). Apart from these standards, two compounds (6a and 6b) were isolated and identified 
(by NMR spectroscopic data) from RMLE as follows.  Briefly, RMLE (1.0 g) was 
subjected to a Medium Pressure Liquid Chromatography (MPLC) column with ODS 
resin.  Then MPLC column was eluted by a combination of water and methanol mobile 
phase (water:methanol, 7:3, v/v).  Subfractions 13-15 were further purified by semi-
preparative HPLC to obtain isomers 6a and 6b.  Their NMR spectroscopic data were in 
agreement with published report (22). 
Quantification of the Levels of the Major Gallotannins Present in Maplifa
tm
 
The contents of identified polyphenols in Maplifa
TM
 were determined by the 
HPLC-UV analytical method that previously reported by our group. Briefly, a stock 
solution of 1 mg/mL of a ginnalin A was prepared in DMSO and then serially diluted to 
afford samples of 0.5, 0.25, 0.125, 0.0625, 0.03125 mg/mL concentrations, respectively. 
Each sample was injected in triplicate and a linear six-point calibration curve (r
2
= 0.9976) 
was constructed by plotting the mean peak area percentage against concentration. All 
HPLC-UV analyses were carried out with 20 μL injection volumes on a Luna C18 
column and monitored at a wavelength of 280 nm. A gradient solvent system consisting 
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of solvent A (0.1% aqueous tri-ﬂuoroacetic acid) and solvent B (methanol, MeOH) was 
used with a ﬂow rate at 0.75 mL/min as follows: 0–50 min, 10%–55% B; 50-51 min, 
55%–100% B; 51-52 min, 100% B; 52-53 min, 100%–10% B. The concentration of 
ginnalin A in the Maplifa
TM
 was quantified based on the standard curves. The 
concentrations of other compounds (1-3 and 5-6) in Maplifa
TM
 were quantified based on 
the percentages of the HPLC area under curve (AUC).  
Biological Evaluations 
Antioxidant Assay (DPPH)  
 The antioxidant potential of the isolated compounds was determined on the basis 
of their ability to scavenge the diphenylpicrylhydrazyl (DPPH) radical according to 
previously reported methods from our laboratory. Ascorbic acid (vitamin C) and the 
synthetic commercial antioxidant, butylated hydroxytoluene (BHT), were used as 
positive controls. The assay was conducted in a 96-well format using serial dilutions of 
50 μL aliquots of test compounds, vitamin C and BHT. After this, 100 μL DPPH (80 
mg/L) was added to each well. Absorbance was determined after 30 min reaction in dark 
at 515 nm by a micro-plate reader (SpectraMax M2, Molecular Devices Corp., operated 
by SoftmaxPro v.4.6 software, Sunnyvale, CA, USA), and the scavenging capacity (SC) 
was calculated as  0 1 0SC% [ A A / A ] 100   , Where A0 is the absorbance of the 
reagent blank and A1 is the absorbance of the test samples.  
Anti-α-Glucosidase Enzyme Assay 
 A mixture of 50 μL of test samples and 100 μL of 0.1 M phosphate buffer (pH 
6.9) containing yeast α-glucosidase solution (1.0 U/ml) were incubated in 96 well plates 
at 25 °C for 10 min. After pre-incubation, 50 μL of 5 mM p-nitrophenyl-α-D-
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glucopyranoside solution in 0.1 M phosphate buffer (pH 6.9) were added to each well at 
timed intervals. The reaction mixtures were incubated at 25 °C for 5 min. Before and 
after incubation, absorbance were recorded at 405 nm by a micro-plate reader 
(SpectraMax M2, Molecular Devices Corp., operated by SoftmaxPro v.4.6 software, 
Sunnyvale, CA) and compared to that of the control which had 50 μL buffer solutions in 
place of the samples. The α-glucosidase inhibitory activity were expressed as percentage 
of inhibition and were calculated as follows: 
     5 0 5 0 5 0inhibition% 100 [ C C S S ] / C C      .  Where C0 is the absorbance of the 
reagent blank in 0 min, S0 is the absorbance of the samples in 0 min, C5 is the absorbance 
of the reagent blank in 5 min and S5 is the absorbance of the samples in 5 min.  
Anti-tyrosinase Enzyme Assay 
Inhibitory effects of gallotannins and a maple leaf extract on mushroom 
tyrosinase was evaluated spectrophotometrically using L-tyrosine as a substrate 
according to a method described previously with minor modification (23). Tyrosinase 
inhibition assays were performed in 96-well microplate format using SpectraMax M2 
microplate reader (Molecular Devices, CA).  Briefly, testing samples were dissolved in 
10% DMSO at a concentration of 5.0 mg/mL and then diluted to different concentrations 
with phosphate buffer (0.1 M, pH 6.8).  Each well contained 40 μL of sample with 80 μL 
of phosphate buffer solution, 40 μL of tyrosinase (100 units/mL), and 40 μL L-tyrosine 
(2.5 mM). The mixture was incubated for 20 min at 37 °C, and absorbance was measured 
at 490 nm. Each sample was accompanied by a blank containing all components except 
L-tyrosine. Arbutin and kojic acid were used as positive controls.  The results were 
compared with a control consisting of 10% DMSO in place of the sample. The 
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percentage of tyrosinase inhibition was calculated as follows: [(ΔAcontrol − ΔAsample)/ 
ΔAcontrol] × 100 
Anti-AGEs Assay (BSA-Glucose Assay) 
The assay was performed as previously reported by our group (24). Briefly, BSA 
(50 mg/mL) was nonenzymatically glycated by incubation under sterile conditions in 1.5 
M phosphate buffer (pH 7.4) at 37 °C for 7 days in the presence of 0.8 M glucose.  
Fluorescence of samples was measured at the excitation and emission maxima of 330 and 
410 nm, respectively, versus an unincubated blank containing the protein, glucose, and 
inhibitors. The % inhibition by different concentrations of inhibitor was calculated as 
[(ΔAcontrol − ΔAsample)/ ΔAcontrol] × 100. Aminoguanidine (AG, 10mM) was used as 
a positive control.  
RESULTS AND DISCUSSION 
 Preparation and Determination of Polyphenol Contents in Maplifa
TM
 
Our laboratory has reported that ginnalin A is a major bioactive compound which 
is predominantly present in various plant parts of the red maple species (21).  In order to 
develop a sustainable source (namely, leaves) of ginnalin A and other bioactive 
compounds, red maple leaves were extracted using 95 % ethanol and subjected to an 
XAD-16 resin column to remove chlorophyll and other plant pigments.  This 
standardized preparation protocol resulted 11.4 % yield of a proprietary extract, named  
Maplifa
TM
, starting from the crude leaves material which was obtained as an off-white 
free flowing dried powder after solvent removal in vacuo.  Because we intended to  
develop Maplifa
TM
 for potential nutraceutical and cosmeceutical applications, instead of 
using laboratory extracting solvents such as methanol or acetone, we used an 
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ethanol/water (95% :5%; v/v) combination which are preferred extraction solvents to 
meet FDA regulatory requirements.   In addition, the total polyphenol contents of 
Maplifa
TM
 were determined as 61.27 % GAEs which was higher than the crude red maple 
leaves extract (as 45.30 % GAEs).  This phenomenon was possibly due to the removal of 
a large fraction of nonpolar or non-phenolic components including chlorophylls and plant 
lipids during the XAD-16 column chromatography.   
Identification of the Major Phytochemicals (Gallotannins) Present in Maplifa
tm
 
 The HPLC-UV chromatogram of Maplifa
TM
 is shown in Figure 2.  The major 
compounds in Maplifa
TM
 were identified as maplexin B (1) (18), ginnalin B (2), ginnalin 
C (3), ginnalin A (4) (17), maplexin F (5) (11) and two isomers (6a and 6b), 6-O-
digalloyl-2-O-galloyl-1,5-anhydro-D-glucitol (6a) and 2-O-digalloyl-6-O-galloyl-1,5-
anhydro-D-glucitol (6b) (22) (Chemical structures shown in Figure 1.).  The chemical 
structures of 6a and 6b were elucidated based on their spectroscopic data, including 
1
H-
NMR and 
13
C-NMR, which were in agreement with previous reports (22).  Compounds 
1-5 were identified by HPLC-UV chromatography profiles by comparison to authentic 
standards.  As shown in Table 1, the HPLC-UV retention time of each peak was 
compared with that of the authentic standards that were previously isolated from maple 
species.  All peaks had identical retention time as comparing with authentic standards 
isolate from red maple barks and twigs (all tR variations were less than 1 min).  In 
addition, the content level (as of weight percentage) of each compound in Maplifa
TM
 was 
determined and shown in Table 1.  Ginnalin A was the predominant compound present in 
Maplifa
TM
 (56.41%) suggesting that Maplifa
TM
 might be able to display similar activities 
compared to ginnalin A alone. 
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Biological Evaluation of Maplifa
TM
 
Maplifa
TM
 was evaluated for anti-oxidant, anti-tyrosinase, anti-α-glucosidase and 
anti-AGEs activities as summarized in Table 2.  In the DPPH assay, Maplifa
TM
 had an 
IC50 value of 78.2 ppm, which was more active more the positive control, a synthetic 
antioxidant, BHT (IC50 = 330.5 ppm).  It has been reported that polyphenolic compounds 
possess potent free radical scavenging capacity and many bioactivities of maple species 
extracts were greatly associated with their polyphenol contents (25).  Based on this anti-
oxidant data, Maplifa
TM
 can be regarded as a polyphenol-rich antioxidant extract of red 
maple leaves.  Furthermore, Maplifa
TM
 also showed a moderate inhibitory effect against 
tyrosinase enzyme.  Although other maple species extracts have been reported as 
inhibitors for tyrosinase and melanogenesis, further investigations such as cellular based 
assays would be necessary to evaluate the skin whiting potency of Maplifa
TM 
(26, 27).  In 
addition, Maplifa
TM
 was assayed for its anti-diabetic activities including anti-α-
glucosidase and anti-AGEs.  The enzyme α-glucosidase is responsible for hydrolysis of 
oligosaccharide into monosaccharide such as glucose, so it is considered as a target for 
the postprandial-hyperglycemia.  Maplifa
TM
 showed superior anti-α-glucosidase 
inhibitory activity compared to the positive control, acarbose (IC50 = 37.8 vs. 91.6 ppm, 
respectively). This result was not unexpected since compound 5 has been previously 
identified as a potent α-glucosidase inhibitor from the red maple bark (19) and other 
compounds in Maplifa
TM
 may also contribute to the activity synergistically.  Lastly, 
Maplifa
TM
 showed a promising inhibitory effect against the formation of AGEs (Figure 3).  
It was approximately 10-fold more potent than aminoguanidine which was used as the 
positive control.  Reactive oxygen species (ROS) and reactive carbonyl species (RCS) are 
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the two factors that accelerate the formation of AGEs, so Maplifa
TM
 might inhibit AGEs 
formation via serving as trapping agent of free radicals and RCS. 
 
 CONCLUSIONS 
 Maplifa
TM
 was developed as a proprietary natural product extracted from red 
maple leaves containing a standardized amount of bioactive ingredients.  This study 
provided preliminary findings of the health beneficial properties of Maplifa
TM
 including 
anti-oxidant, anti-tyrosinase, anti-α-glucosidase and anti-AGEs effects.  Further 
investigation of Maplifa
TM
 is warranted to evaluate the skin-whitening effect at cellular 
and molecular level and the mechanisms of its anti-diabetic activities.  Overall, 
Maplifa
TM
 was developed as a sustainable source (using leaves) for bioactive compounds 
from the red maple species with nutraceutical and/or cosmeceutical potential. 
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FIGURE AND TABLE LEGEND 
Figure 1. Chemical structures of maplexin B (1), ginnalin B (2) and ginnalin C (3) 
ginnalin A (4), maplexin F (5) and 6-O-digalloyl-2-O-galloyl-1,5-anhydro-D-glucitol 
(6a) and 2-O-digalloyl-6-O-galloyl-1,5-anhydro-D-glucitol (6b) identified from 
Maplifa
TM
.  All the compounds were identified based on comparing their HPLC-UV peak 
retention time (tR, min) with that of the authentic standards.  
Figure 2.  HPLC-UV chromatograms of Maplifa
TM
 showing the presence of major 
polyphenolic compounds.  Peak 1 = maplexin B; Peak 2 = ginnalin B; Peak 3 = ginnalin 
C; Peak 4 = ginnalin A; Peak 5 = maplexin F; Peak 6a/6b (co-eluting) = 6-O-digalloyl-2-
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O-galloyl-1,5-anhydro-D-glucitol (6a) and 2-O-digalloyl-6-O-galloyl-1,5-anhydro-D-
glucitol (6b), respectively. Chromatograms were monitored at a wavelength of 223 nm. 
Figure 3. Inhibitory effect of Maplifa
TM
 against the formation of AGEs. 10 mg/ml BSA 
and 100 mM D-fructose were incubated at 37 °C in 0.2 M phosphate buffer, pH 7.4. Prior 
incubation, each sample was treated with different concentrations of Maplifa
TM
 or 
aminoguanidine serving as positive control. After incubating for 21 days, the formation 
of fluorescence AGEs in each solution was determined at excitation and emission 
wavelengths of 370 nm and 435 nm respectively. Each fluorescence reading was then 
compared to the intensity of negative control solution. 
Table 1.  The HPLC-UV retention times (min) of major compounds present in Maplifa
TM
 
as comparing with of those authentic standards.  The contents of identified compounds 
were determined by standard curve of authentic standards. 
Table 2.  Biological evaluation of Maplifa
TM
 showing 50% inhibitory concentrations 
(IC50 in ppm) in the antioxidant (DPPH radical scavenging), anti-tyrosinase, anti-α-
glucosidase and anti-AGEs (BSA-glucose) assays.  Values are means  standard 
deviations.  
a
Positive controls, ascorbic acid and BHT.  
b
Positive control, kojic acid and 
arbutin.   
c
Positive control, acarbose.  
d
Positive control, aminoguanidine. 
  
 
19 
 
Figure 1. 
O
O
O
O
OH
HO
HO
O
HO OH
OH
O
HO
O
HO
HO
HO
O
O
O
O
OH
HO
HO
HO
HOO
OH
OH
HO
O
OH
O
O
HO OH
OH
HO
HO
maplexin B (1) ginnalin C (3)
ginnalin A (4)
maplexin F (5)
O
O
OH
O
OH
HO
HO
HO
HO
ginnalin B (2)
O
O
OH
HO
HO
O
HO OH
OH
O
O
O
O
R1
HO
HO
HO
HO
O
HO OH
R2
6a: R1=OH; R2=galloyl
6b: R1=galloyl; R2=OH
OH
HO
HO
O
galloyl
O
 
 
  
 
20 
 
Figure 2. 
 
 
 
  
 
21 
 
Figure 3. 
 
 
  
 
22 
 
Table 1. 
      
 Peak tR (min) standards (tR, min) Content (weight %) 
1 18.84 18.84 6.48 
2 26.55 26.5 5.66 
3 27.41 27.53 5.28 
4 47.13 47.09 56.41 
5 49.22 50.01 4.83 
6a, 6b* 51.74 52.67 12.1 
    *compounds isolated and identified by NMR data
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Table 2. 
     
 Anti-
oxidant 
Anti-tyrosinase Anti-α-
glucosidase 
Anti-AGEs 
 DPPH   BSA-glucose assay 
Maplifa
TM
 78.2 ± 2.6 154.5 ± 5.4 37.8 ± 3.3 8.6 ± 0.7 
BHT
a 
330.5 ± 8.4 − − − 
ascorbic acid
a 
10.9 ± 0.7 − − − 
kojic acid
b − 3.4 ± 1.3 − − 
arbutin
b − 17.1 ± 2.4 − − 
acarbose
c − − 91.6 ± 3.8 − 
aminoguanidine
d − − − 83.9 ± 2.1 
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ABSTRACT 
 Bioactive gallotannins have been researched extensively for α-glucosidase 
inhibitors.  Our previous phytochemical studies on the red maple (Acer rubrum) species 
lead to the identification of a series of gallotannins with potent α-glucosidase inhibitiory 
activties.  In the present study, we aimed to provide insights into the ligand-enzyme 
interactions and the binding mechanisms of gallotannins and the α-glucosidase enzyme.  
The inhibitory effects of four gallotannins: ginnalin A (GA), ginnalin B (GB), ginnalin C 
(GC) and maplexin F (MF) from the red maple species, as well as a synthetic gallotannin, 
maplexin J (MJ), were evaluated for α-glucosidase inhibitory activity.  The type of GA, 
MF and MJ was determined as noncompetitive mode.   The interactions between 
gallotannins with potent inhibitory activities (MF and MJ) and α-glucosidase were further 
elucidated by using spectroscopic means. The results revealed that gallotannins inhibited 
α-glucosidase by forming stable ligand-enzyme complexes which consequently lead to 
the quenching of their intrinsic fluorescence statically.  In addition, fluorescent probe 
1,1′-bis(4-anilino-5-napththalenesulfonic acid (bis-ANS), was used to explore the regions 
that gallotannins bound to.  Meanwhile, the FTIR and circular dichroism spectra showed 
that gallotannins bound to α-glucosidase and induced conformational changes to the 
enzyme.  These findings were further discussed in the context of structure activity 
relationship (SAR) for the potential of developing structural gallotannin analogs as potent 
α-glucosidase inhibitors. 
Keywords: α-glucosidase, gallotannins, inhibition, mechanisms, interaction. 
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INTRODUCTION 
 In mammals, enzymes involved in the carbohydrate processing pathways are 
therapeutic targets for various diseases including diabetes, cancer and viral infections (1-
3).  Among these enzymes, glucosidases (EC 3.2.1.20) play a crucial role in the 
mediation of carbohydrate metabolism by catalyzing the cleavage of the glycosidic 
linkage of oligosaccharides or glycoconjugates to release mono-saccharides (4).  
Inhibition of glucosidase results in a retardation of glucose absorption and consequently 
decreases the postprandial blood glucose level.  Therefore, development of α-glucosidase 
inhibitors as a class of antihyperglycemic drugs for the type II non-insulin-dependent 
diabetes mellitus (NIDDM) has drawn considerable research attention (5).  In fact, 
several synthetic α-glucosidase inhibitors (AGI) including acarbose, miglitol and 
voglibose are currently used as clinical treatments for NIDDM (Figure 1A).  However, 
applications of these AGIs as therapeutic agents suffered due to a lack of efficacy and 
undesirable side effects such as flatulence, diarrhea and stomachache (6).  On the other 
hand, plant-based natural products are a promising resource of possible alternative AGIs 
since they possess a variety of chemical structures and bioactivities.  The genus Acer 
(family, Aceraceae), commonly known as maple, consists of more than 120 species and 
are widely distributed in Asia, Europe and North America. Among these species, the Acer 
rubrum (red maple) is indigenous to North America and has been used as for 
ethnomedicinal purposes by the indigenous peoples of eastern North America to treat 
many ailments such as sore eyes and skin disorders (7).  Phytochemical and biological 
investigations have shown that extracts and their purified compounds from red maple 
displayed biological activities including anti-oxidant, anti-bacterial and anti-cancer 
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effects (8-10).  Interestingly oral administration of red maple bark extract to mice was 
shown to decrease the elevation of their blood glucose level after carbohydrate ingestion 
(11).  As maple phytochemicals seemed to be effective in decreasing mouse postprandial 
blood glucose levels, it was important to understand the mechanisms of this specific 
bioactivity.  
As a continuous effort of exploring plant natural products with biological 
activities, our laboratory isolated a number of new gallotannins from Acer (maple) 
species, namely maplexins A-I (12, 13).  These compounds feature different numbers and 
positions of galloyl groups attached to a 1,5-anhydro-D-glucitol moiety.   These 
compounds, in particular maplexins E-I, were shown to be potent AGIs, 20-fold more 
potent than acarbose.  Moreover, the structure and activity relationship (SAR) studies 
revealed that maplexins showed superior inhibitory activity against α-glucosidase as the 
number of the galloyl groups on 1,5-anhydro-D-glucitol increased (12, 13).  Furthermore, 
our laboratory synthesized maplexin J, a tetragalloyl-glucitol (contains the maximum 
number of 4 galloyl groups) and substantiated our SAR observations on α-glucosidase 
inhibition.  It is logical to question how maplexins bind to α-glucosidase and what types 
of interactions between the ligands and enzyme lead to the inhibitory effects.  This 
information is essential for the design and development of effective maple-gallotannin-
based AGIs and the effective utilization of red maple species extracts as potential anti-
diabetic therapeutics.   
The natural products based α-glucosidase inhibitors such as 1-deoxynojirimycin, 
resveratrol and oxyresveratrol can be distinguished by their inhibitory types.  Moreover, 
the mechanisms of their inhibitory effects on α-glucosidase could also be demonstrated 
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by a series of physicochemical features such as binding to the catalytic domain, 
modifications of hydrophobicity surface and conformational changes of enzyme that 
induced by the binding ligands (14).  In this study, enzymatic kinetics along with 
biophysical tools including fluorescence spectroscopy and circular dichroism (CD) were 
used to elucidate the inhibitory mechanisms of maple gallotannins against α-glucosidase. 
 
MATERIALS AND METHODS  
Chemicals. α-Glucosidase (EC 3.2.1.20) from Saccharomyces cerevisiae, p-Nitrophenyl-
α-D-glucopyranoside (pNPG) and bis-8-anilinonaphthalene-1-sulfonate (bis-ANS) were 
purchased from Sigma–Aldrich (St. Louis, MO).   All other chemicals were analytical 
reagent grade and purchased from Sigma–Aldrich, unless otherwise specified.  Maplexin 
F was previously isolated from our laboratory (13) and maplexin J was synthesized in our 
laboratory as described below. 
Synthesis of Maplexin J.  Trisilyl-protected gallic acid (Previously synthezied in our lab, 
187 mg, 0.4 mmol) and glucitol (, 10.4 mg, 0.06 mmol) were dissolved in dry 
dichloromethane ( 2 mL). N,N'-diisopropylcarbodiimide (61.4 mg, 0.5 mmol) was added 
followed by 4-dimethylaminopyridin (74.4 mg, 0.06 mmol). The mixture was stirred at 
room temperature under nitrogen for 96 h. Water was added to the reaction mixture, and 
the solution was extracted (× 3) using ethyl acetate. The combined organic layer was 
washed with brine solution, dried over anhydrous sodium sulfate, and concentrated. The 
crude product was purified using silica gel column chromatography to yield compound 1. 
The esterification products were isolated using silica gel chromatography with a gradient 
solvent system of hexanes:ethyl acetate starting with hexanes at 100%.  The deprotection 
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of compound 1 was accomplished in the presence of tetra-n-butylammonium fluoride. 
Compound 1 (50 mg, 0.023 mmol) was dissolved in dry tetrahydrofuran (2 mL). Tetra-n-
butylammonium fluoride (61.1 mg, 0.23 mmol) was added, and the mixture was stirred at 
room temperature under a nitrogen atmosphere for 10 min. The crude product was 
purified using reverse-phase HPLC to yield the final product (10 mg, 52.3%) which was 
characterized and assigned the common name of maplexin J. 
α-Glucosidase Inhibitory Assay. 
  A mixture of 50 μL of test samples and 100 μL of 0.1 M phosphate buffer (pH 
6.9) containing yeast α-glucosidase solution (1.0 U/ml) were incubated in 96 well plates 
at 25 °C for 10 min. After pre-incubation, 50 μL of 5 mM p-nitrophenyl-α-D-
glucopyranoside solution in 0.1 M phosphate buffer (pH 6.9) were added to each well at 
timed intervals. The reaction mixtures were incubated at 25 °C for 5 min. Before and 
after incubation, absorbance were recorded at 405 nm by a micro-plate reader 
(SpectraMax M2, Molecular Devices Corp., operated by SoftmaxPro v.4.6 software, 
Sunnyvale, CA, USA) and compared to that of the control which had 50 μL buffer 
solutions in place of the samples. The α-glucosidase inhibitory activity were expressed as 
inhibition % and were calculated as follows: 
     5 0 5 0 5 0inhibition% 100 [ C C S S ] / C C      .Where C0 is the absorbance of the 
reagent blank in 0 min, S0 is the absorbance of the samples in 0 min, C5 is the absorbance 
of the reagent blank in 5 min and S5 is the absorbance of the samples in 5 min (15).  
Kinetics of Enzyme Inhibition. 
 The inhibition types of ginnalin A and maplexins F and J were determined from 
Lineweaver–Burk plots, using methods reported in literatures with minor modification. 
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Typically, two concentrations of each sample around the IC50 values were chosen. Under 
each concentration, α-glucosidase activity was tested by different concentrations of 
pNPG glycoside (1 to 1000 μM). The enzyme reaction was performed under the above-
mentioned reaction condition. The mixtures of the enzyme and the inhibitor were 
dissolved in 50 mM phosphate buffer (pH 6.8), and pre-incubated at 37 °C for 30 min, 
and then the substrate was added. The enzymatic reaction was carried out at 37 °C for 
60 s, and monitored spectrophotometrically by measuring the absorbance at 405 nm. 
Inhibition types of the inhibitors were determined by Double-reciprocal plots (16). 
Instrinsic Fluoescence Measurements. 
 α-Glucosidase (2 μM) was pretreated with various concentrations of MF or MJ 
(0–60 μM) for 20 min at 37 °C. The intrinsic fluorescence spectra (300–400 nm) were 
measured using a micro-plate reader (SpectraMax M2, Molecular Devices Corp., 
operated by SoftmaxPro v.4.6 software, Sunnyvale, CA, USA) with the excitation 
wavelength (λex) of 280 nm, and emission (λem) spectra were acquired by scanning from 
300 to 340 nm (17). 
Hydrophobic Analysis of α-Glucosidase Using Bis-ANS. 
 α-Glucosidase (2 μM) was incubated in the presence of various concentrations of 
gallotannins (0-80 μM) at 37 °C for 5 min. Bis-ANS (5 μM) was then added, and 
fluorescence was measured after incubation at 37 °C for 15 min (λex = 400 nm, λem = 
440−600 nm) (18). 
ATR-FTIR Measurements. 
 The FTIR spectra of α-glucosidase (2 μM) and its maplexins complex were 
measured in   the range of 2000–1400 cm−1 in sodium phosphate buffer, pH 6.8 at room 
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temperature.  All spectra were recorded by using the ATR mode with the resolution of 4 
cm
−1 
and 60 scans.  The final concentration of maplexins was 40 μM.  The corresponding 
absorbance of free maplexins and buffer solutions were recorded and subtracted with the 
same instrumental conditions.  The curve-fitted results of amide I band and all data were 
analyzed using Omnic software (version 7.2, Nicolet Instrument Co, Madison, WI, USA), 
and the curves were fitted using Origin software (version 8.0, Origin Lab, Northampton, 
MA, USA) (19). 
Circular Dichroism (CD) Spectroscopy. 
 Far UV CD measurements (190-240 nm) were conducted on a Jasco J-810 
spectropolarimeter equipped with a Peltier temperature controller at 25 °C. Briefly, 2 μM 
of α-glucosidase was treated with various concentrations of a gallotannins (0-80 μM). 
The samples were dissolved in 200 µL of a sodium phosphate buffer (0.1 M, pH 6.8) and 
placed in a 1.0 mm path length cell.  The spectra were collected and corrected by 
subtraction of a blank 0.1 M sodium phosphate buffer (pH 6.8), reduction of noise and 
smoothing (20).  The changes of secondary structure of α-glucosidase were estimated 
according to a method of DichroWeb program, an online server for protein secondary 
structure analyses from CD spectroscopic data (21, 22). 
 
RESULTS 
Comparison of α-Glucosidase Inhibitory Effects by Gallotannins.   
As shown in Table 1, the inhibition of α-glucosidase by maple gallotannins was 
enhanced by increasing the number of galloyl groups that attached to the 1,5-anhydro-D-
glucitol moiety.  The mono-galloyl substituted gallotannins (ginnalin B and C) did not 
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show the inhibitory activities on glucosidase (IC50 > 1000 μM), and the di-galloyl 
gallotannin (GA) only showed a moderate inhibitory activity at an IC50 value of 216.43 
μM.  However, the activities of maplexin F (MF) and maplexin J (MJ), were significantly 
more potent (IC50 = 13.70 and 4.27 μM, respectively) at inhibiting α-glucosidase. 
 To further elucidate the inhibitory characteristics of GA, MF and MJ, the enzyme 
kinetics were determined by using Lineweaver-Burk plots (Figure 2).  The Lineweaver-
Burk plot of each gallotannin at different concentrations generated straight lines that had 
the same intersections on the X-axis suggesting that all three gallotannins were typical 
noncompetitive α-glucosidase inhibitors.  This means that GA, MF and MJ bound to a 
site on α-glucosidase other than the catalytic domain of the enzyme (23). 
Gallotannins Binding Quenched the Intrinsic Fluorescence of α-Glucosidase.   
Both MF and MJ displayed potent inhibitory activity in a non-competitive model 
indicating that these gallotannins bound a non-catalytic domain of α-glucosidase.  
Therefore, an intrinsic fluorescence assay was carried out to further explore the 
interaction between ligands and α-glucosidase.  As shown in Figure 3, the α-glucosidase 
fluorescence emission spectra showed a peak at 312 nm, which was largely attributed to 
the tryptophan residues of α-glucosidase. Neither MF nor MJ show any intrinsic 
fluorescence.  The fluorescence intensity of α-glucosidase was gradually quenched when 
it was co-incubated with maplexins at various concentrations.  Maplexins clearly 
quenched α-glucosidase fluorescence at a comparable level (both MF and MJ had a 
quenching ratio of 21%) when their concentration was increased to 60 μM, suggesting 
that ligands (MF and MJ) interacted with α-glucosidase which further leaded to the 
variation of tryptophan residues. 
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Gallotannins Binding Reduced the Hydrophobicity of α-Glucosidase.   
Noncovalent fluorescent probes have been well developed for the study of protein 
conformation (24, 25).  External fluorescent probes such as bis-8-anilinonaphthalene-1-
sulfonate (bis-ANS) are sensitive to the protein microenvironment and selectively binds 
to the hydrophobic surface of protein.  Therefore, bis-ANS probe was utilized to assess 
the α-glucosidase hydrophobic surface.  As shown in Figure 4, after co-incubated with α-
glucosidase for 20 min at 37 °C, MF and MJ were able to decrease the fluorescence of 
bis-ANS-enzyme complex in a concentration-dependent manner.  Both ligands clearly 
reduced the fluorescence intensities at concentration of 80 μM, suggesting that MF and 
MJ could decrease the hydrophobic surface of α-glucosidase. Although at a low 
concentration (20 μM), MJ also induced a large change in hydrophobic surface.  Because 
hydrophobic interactions are an important part of the enzyme active site, it is reasonable 
to suggest that MF and MJ inhibit α-glucosidase activity by inducing poor hydrophobic 
surface interactions in the enzyme active site (25).  
FTIR Spectroscopic Analysis of α-Glucosidase.   
In order to study the impact of the ligands on the conformational changes of α-
glucosidase, ATR-FTIR spectra of α-glucosidase and α-glucosidase-ligands complex 
were obtained.   It has been known for the use of infrared spectroscopy for the study of 
proteins and the focuses have been placed on the amide I and II bands which represent 
different vibrations of the amino acid residues from proteins.  As shown in Figure 5 A, 
free α-glucosidase had a strong peak of amide I region (1700-1600 cm-1 and 1600-1500 
cm
-1, mainly contribution of C=O stretch and C−N stretch, respectively) (19, 26).  Co-
incubation of α-glucosidase with ligands, for example maplexin F as shown in Figure 5 
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B, induced the shift of amide I band (1637 cm
-1
)
 
and amide II band (1564 cm
-1
) to 1633 
cm
-1
 and 1541 cm
-1
, respectively.  The similar amide band shift pattern was also observed 
in the MJ-α-glucosidase complex FTIR spectra suggesting that maplexins F and J 
interacted with the C=O and C−N groups in the α-glucosidase subunit and might further 
induce the change of carbonyl hydrogen binding pattern. 
Change in Conformation of α-Glucosidase Induced by Maplexins F and J.   
In order to further examine the effects of ligands on the secondary structure of α-
glucosidase, circular dichroism (CD) spectra of free α-glucosidase and maplexin-α-
glucosidase complex were acquired.  In the Figure 6, CD spectra of free α-glucosidase 
exhibited two characteristic negative bands at 208 and 222 nm indicating that the major 
secondary protein structure present in the α-glucosidase was α-helix.  When 20 or 40 μM 
of ligands were co-incubated with α-glucosidase, they had the identical CD spectra as 
that of free α-glucosidase, however, the CD spectra of ligands-enzyme complex 
significantly altered when the concentrations of maplexins reached to 60 or 80 μM 
indicating that the conformation of enzyme protein was affected by the ligands in a 
concentration dependent manner.  As summarized in Table 2, maplexins bind to the 
enzyme protein and mainly resulted in the loss of α-helix conformation.  For instance, 
when 80 μM of MF and MJ were induced to α-glucosidase, it lost 14.8 and 15.0% of α-
helix conformation respectively, which might lead to the lost of its biological function. 
 
DISSCUSSION AND CONCLUSSION   
 Red maple (Acer rubrum) is one of the Acer (maple) species that is widely 
distributed in eastern North America and it is known for its sap which is used for the 
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production of maple syrup.  It has been used by the indigenous peoples of eastern North 
America as food resource or herbal medicine (27).  Recent phytochemical and biological 
studies lead to the discovery of bioactive compounds from red maple species that 
potentially could be used as therapeutic approaches for diabetes (11-13).  Among these 
compounds, maplexins (F and J), as the representatives of a large group of gallotannins, 
showed 20-30 times more potent inhibitory effects against α-glucosidase than acarbose (a 
clinically used AGI drug).  However, the mechanisms of action of maplexins on α-
glucosidase were unknown.  Therefore, we initiated this study to explore the interactions 
between maplexins and α-glucosidase by using kinetic assay and a set of spectroscopic 
methods.  Firstly, the inhibition type of GA, MF and MJ against α-glucosidase was 
determined as noncompetitive mode suggesting that these gallotannins bonded to a 
specific site of enzyme-substrate complex rather than the enzyme catalytic domain.  This 
binding pattern distinguishes maple gallotannins from the other known clinically used 
drugs, such as acarbose, which is known as a competitive inhibitor that directly binds to 
the active site of α-glucosidase (6).  This finding was in agreement with previous studies 
that demonstrated a few of other gallotanins, including pentagalloyl glucose (PGG), are 
noncompetitive α-glucosidase inhibitors (28).  In addition, it was demonstrated that 
increasing of numbers of galloyl groups on the glucitol core could enhance inhibitory 
activities of maplexins and this SAR effects were also observed in other glucose-based 
gallotannin α-glucosidase inhibitors (29).  Interestingly, MJ as a fully galloyl substituted 
glucitol gallotannin (four galloyl groups, IC50 =4 μM) seemed to be more potent than 
PGG, a gallotannin with a glucose core and maximum numbers of galloyl groups (five 
galloyl groups, IC50 = 130.71 μM).  It is speculated that the absence of galloyl group at 
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the glucitol C-1 position facilitated the formation of a favorable binding site for 
maplexins and further enhanced their inhibitory effects against α-glucosidase.   
 In order to get further insight of the interaction between maplexins and α-
glucosidase, fluorescence quenching assay was performed.  Since the intrinsic 
fluorescence of α-glucosidase mainly contributed from tryptophan residues and its 
intensity could be quenched by maplexins in a concentration dependent manner, it 
confirmed that maplexins could directly bind to α-glucosidase and possibly lead to the 
variation of microenvironment of tryptophan residues.  This observation was consistent 
with many previously demonstrated ligands-protein interactions.   
 Hydrophobic surface is another important factor for maintaining the normal 
functions of proteins.  It has been established that enzyme activity suffers from the 
exposure of hydrophobic surface to water, which usually impede the formation of the 
active center (30).  Fluorescent probes such as 4,4'-dianilino-1,1'-binaphthyl-5,5'-
disulfonic acid (bis-ANS) have been used to monitor the hydrophobic surface of α-
glucosidase (31).  The bis-ANS probe can specifically bind to the hydrophobic area of the 
enzyme and then generate fluorescent signal.  Therefore, the decreased fluorescent 
intensity of probe-ligands-enzyme complex indicated that maplexins could reduce the 
hydrophobic surface of enzyme. 
 FTIR spectroscopy has been widely used to study the conformation of protein and 
it is often complemented by other physical tools such as circular dichroism (CD) for 
detailed secondary structural changes.  The FTIR spectra clearly showed that maplexins 
interacted with the C=O and C−N groups of α-glucosidase subunits and lead to the peak 
shift of amide I band.  In addition, the secondary structures of α-glucosidase were 
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monitored by CD spectra and it demonstrated that both maplexins F and J significantly 
decreased the α-helix conformation.  Since it is known that α-helix is a rigid secondary 
structure and loss of it may result in the destabilization of enzyme conformation (32).  In 
a word, maplexins inhibited α-glucosidase activity by binding to the enzyme-substrate 
complex and consequently changed the hydrophobic surface and enzyme secondary 
conformation. 
 In summary, we have determined the type of inhibition of maple gallotannins GA, 
MF and MJ.  Two potent α-glucosidase inhibitors, MF and MJ, were further studied for 
the ligands-enzyme interaction by using several biophysical tools.  It has been showed 
that maplexins could affect enzyme activity by decreasing the hydrophobic surface of 
enzyme as well as reducing the α-helix conformation.  The inhibitory mechanisms of 
maplexins provide valuable information towards the understanding of interactions 
between maple gallotannins and α-glucosidase.  This is critical for the potential 
application of maplexins or maple species extracts as therapeutics for the NIDDM.  
Further investigation of the anti-diabetic properties of maple gallotannins will be focused 
on: 1) the possible synergistic anti-α-glucosidase effects of bioactive compounds that are 
totally present in the red maple extracts and 2) in vivo studies that evaluate the efficacy of 
anti-diabetic property of maplexins.  These information are crucial for the development 
of red maple leaf extracts as potential nutraceutical and dietary management for type 2 
diabetes 
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FIGURE AND TABLE LEGEND 
Figure 1: (A) Chemical structures of known clinical used α-glucosidase inhibitors: 
acarbose, miglitol and voglibose.  (B) Chemical structures of five gallotannins: ginnalin 
A, ginnalin B, ginnalin C, maplexin F and maplexin J. 
Figure 2: Lineweaver-Burk plots of the kinetics of GA (A), MF (B) and MJ (C) on α-
glucosidase.  Two concentrations of ligands that near to the IC50 were co-incubated with 
α-Glucosidase at 37 °C for 30 min, then pNPG were added with final concentrations from 
1-1000 μM. 
Figure 3: Intrinsic fluorescence of α-glucosidase quenching induced by MF (A) and MJ 
(B). α-Glucosidase (2 μM) was co-incubated with MF (0-60 μM) or MJ (0-60 μM) at 37 
°C for 20 min.  Spectra were acquired from 300 to 340 nm. 
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Figure 4: Fluorescence intensity of bis-ANS-α-glucosidase complex.  The changes of 
fluorescence intensity were induced by MF (A) and MJ (B) at different concentrations. 
Figure 5: The ATR-FTIR of free α-glucosidase (A) 2 μM of α-glucosidase and 40 μM of 
MF (A) or MJ (B) complex. 
Figure 6: Circular dichroism spectra of the α-glucosidase-maplexins complex.  α-
Glucosidase (2 μM ) were  co-incubated with MF or MJ at 20-80 μM at 37 °C for 20 min. 
Table 1: α-Glucosidase inhibitory activities of compoundsa 
Table 2: The effect of maplexins (MF and MJ) on the secondary structure of α-
glucosidase. 
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Figure 6. 
(A) 
 
(B) 
 
  
50 
 
Table 1  
   
    
Compd. 
# of 
galloyl 
groups 
IC50 (μM) Type of inhibition 
ginnalin B 1 > 1000 n.d. 
ginnalin C 1 > 1000 n.d. 
ginnalin A  2 216.43 ± 3.19 noncompetitive 
maplexin F  3 13.70 ± 0.87 noncompetitive 
maplexin J  4 4.27 ± 0.13 noncompetitive 
acarbose
 b
 ─ 142.40 ± 1.68 competitive[6] 
PGG
c
 5 130.71 ± 4.37 noncompetitive
[28]
 
   
    
 
a IC50 values are shown as mean ± S.D. from three independent experiments; 
b Positive control; n.d. = not 
determined.  cPGG (Pentagalloyl glucose, previously isolated in our laboratory) showed an IC50value of 
130.71 ± 4.37 μM. 
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Table 2 
   
 
        
Inhibitor 
conc. 
(μM) 
α-helix 
(%) 
α-helix 
loss (%) 
β-sheet 
(%) 
β-turn 
(%) 
random 
coil(%) 
free α-
glucosidase   42.3 − 33.4 1.2 23.1 
MF 20 42.3 0 33.6 1.4 22.7 
 
40 43 -0.7 36.7 -1.3 21.6 
 
60 30.9 11.4 35.8 9.8 23.5 
 
80 27.5 14.8 40.1 6.5 25.9 
MJ 20 44.1 -1.8 32.5 0.9 22.5 
 
40 43.6 -1.3 35.4 -0.7 21.7 
 
60 26.9 15.4 40.8 4.9 27.4 
  80 27.3 15 39.2 8 25.5 
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ABSTRACT 
 Glycation is a spontaneous process typically initiated with a condensation reaction 
between a reducing sugar and a protein, leading to the formation of Advanced Glycation 
Endproducts (AGEs). Glycation is a spontaneous non-enzymatic process leading to the 
formation of Advanced Glycation Endproducts (AGEs).  The reaction is typically 
initiated through a condensation reaction between a reducing sugar and a protein. The 
objective of this study was to evaluate the inhibitory effects of a series of maple 
gallotannins, namely ginnalins A-C and maplexins F and J, at individual stages of protein 
glycation. Using a combination of analytical methods, including fluorescence 
spectroscopy, HPLC-FL, Circular Dichroism, MALDI-TOF and BSA-fructose assay, 
early and middle stages of protein glycation inhibition by maple gallotannins were 
determined. In the BSA-fructose assay, maplexin F showed the most potent inhibitory 
effect against the formation of AGEs with an IC50 value of 15.8 µM.  In addition, 
MALDI-TOF analysis revealed that the maple gallotannins were able to reduce the 
number of fructose that adducted to BSA protein indicating that they were able to inhibit 
the production of Amadori products. Moreover, maple gallotannins were effective in the 
G.K. peptide-ribose assay suggested that the protein cross-linking formation at the late 
stage of glycation could be prevented by maple gallotannins.  Lastly, the spectroscopy 
data revealed that maple gallotannins were able to reduce the conformational changes of 
BSA protein that induced by glycation. 
Keywords: maple gallotannins, glycation, FL-HPLC, MOLDI-TOF-MS, G.K. peptide, 
circular dichroism 
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INTRODUCTION 
 The Maillard reaction, also referred to as glycation, is a non-enzymatic process 
including a reducing sugar and an amino containing molecule such as protein, lipid or 
nucleotide (1). The process of glycation includes three distinguishable phases: the initial 
stage, the intermediate stage and the late stage. In the initial phase of glycation, the 
carbonyl group of a reducing carbohydrate condenses with the free amino group on a 
protein to reversibly form glycosylamine.  Glycosylamine can be further converted to a 
more stable aldimine, or Amadori product (2). Under appropriate conditions, these 
Amadori products can be degraded to generate more reactive dicarbonyls such as 
methylglyoxal (MGO), glyoxal (GLY) and 3-deoxyglucosone (3-DG) (3, 4).  These 
dicarbonyl compounds can in turn continue to react with unmodified proteins and/or 
Amadori products.  In the late stage of glycation, the Amadori product could undergo 
dehydration, cyclization, oxidation, and rearrangement to form a polymorphic group of 
compounds collectively known as Advanced Glycation Endproducts (AGEs) (5, 6). 
The accumulation of AGEs in vivo has been implicated as a major pathogenic factor 
in diabetic chronic complications such as renal failure, cataract formation, Alzheimer’s 
disease and cardiovascular disease (7-9). Most of the glycation related chronic 
complications are due to the AGE accumulation on long-lived proteins such as collagen 
and lens crystallins. Glycation can also induce the formation of reactive oxidation species 
(ROS), causing oxidation stress and tissue damage (10). 
Aminoguanidine (AG) is a synthetic chemical that acts as anti-glycation agent by 
preventing the formation of reactive oxygen species, however due to potential side effects 
did not propagate to clinical use (11).  Polyphenolic compounds from plant sources, such 
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as curcumin and resveratrol, have drawn considerable research interests for their 
biological activities including anti-oxidant and anti-AGEs formation effects (12, 13).  
Moreover, polyphenols isolated from many maple (Acer) species including ginnalins A-C 
(Figure 1) are known for their free radical scavenging capacity and other bioactivities 
(14, 15).  Recently, a series of maple gallotannins, namely maplexins E-I, as well as a 
synthetic analogue maplexin J (Figure 1), were reported for their anti-diabetic effects as 
potent anti-α-glucosidase inhibitors in a structure dependent manner (16, 17).  Due to 
aforementioned biological and SAR activities, it is interesting to evaluate maple 
gallotannins for further anti-diabetic potential.  However, to our best knowledge, maple 
gallotannins have never been reported for the anti-AGEs formation effects.  Therefore, 
we initiated this study to evaluate the inhibitory effects of maple gallotannins in the early, 
middle and late stages of protein glycation. 
 
MATERIALS AND METHODS  
 Chemicals 
Bovine serum albumin (BSA), sodium azide, D-fructose, methylglyoxal (MGO), 
aminoguanidine (AM), 1,2-phenylenediamine (PD), 2,3-dimethylquinoxaline (DQ), 
sinapic acid were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). 
HPLC-grade acetonitrile and trifluoroacetic acid (TFA) were procured from Thermo 
Fisher Scientific (Rockford, IL, USA). ZipTip pipette tips with C4 resin and 0.22 µm 
filter unit were obtained from EMD Millipore Co. (Billerica, MA, USA).  
BSA-Fructose Assay 
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The BSA-fructose assay was used to evaluate the inhibitory ability of PGG on 
early and middle stage of BSA glycation according to the methods described previously 
(18).  Briefly, bovine serum albumin was glycated using fructose as a glycating agent. 
The reaction mixtures contained 20 µM BSA with 20 mM fructose in a final volume of 3 
mL of the 20 mM sodium phosphate buffer, pH 7.0 containing 0.2 M NaCl and incubated 
at 37°C for different time intervals (7–21 days). 
Preparation of Reaction Mixtures 
In brief, stock solutions of BSA (50 mg/ml) and D-fructose (200 mM) were 
prepared in 0.2 M phosphate buffer, pH 7.2. Blank solutions included either BSA alone 
(10 mg/ml) or D-fructose alone (100 mM) in 0.2 M phosphate buffer. Negative control 
solutions included 10 mg/ml BSA and 100 mM D-fructose in the absence of maple 
gallotannins. The negative control mixtures was then mixed with different amount of 
maple gallotannins, resulting in the final concentrations of 1, 5, 10, 20, 50, 100, 200 and 
400 µM. 10 mg/ml BSA and 100 mM D-fructose incubated with different concentrations 
of aminoguanidine served as positive control solutions. Unless otherwise indicated, all 
reaction mixtures were prepared in triplicate and incubated at 37 °C in a shaking water 
bath for a total length of 21 days. During incubation, aliquots were drawn from the 
reaction mixtures on day 3, day 7, day 14 and day 21 and stored at -20 °C until analysis. 
Analysis of the mixtures was performed on samples that were thawed, centrifuged and 
purified by ZipTip pipettes, EMD Millipore Co. (Billerica, MA, USA). 
Fluorescence Spectroscopy 
Prior to analysis, 40 µl of each sample was diluted 5 fold with 0.2 M phosphate 
buffer, pH 7.2 and then transferred to 96-well black fluorescence reading plates. 
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Fluorescence measurements for monitoring glycated products were then carried out with 
a Spectra Max M2 spectrometer (Molecular Devices, Sunnyvale, CA, USA) at excitation 
and emission wavelengths of 340 nm and 430 nm, respectively. The above excitation and 
emission values were optimal for detecting all of the BSA AGEs.  
MALDI-TOF Mass Spectrometry 
Intact BSA samples were purified and concentrated using C4 ZipTips and 
analyzed on a Bruker Autoflex MALDI-TOF mass spectrometer. Prior to analysis, the 
purified protein samples (0.7 μL) were each mixed with a 50% aqueous acetonitrile 
solution (0.7 μL) of saturated α-cyano-4-hydroxy-cinnamic acid containing 0.05% TFA 
as matrix, spotted onto a stainless steel sample plate and allowed to air dry. Samples were 
analyzed on a Bruker Autoflex MALDI-TOF mass spectrometer with instrument settings 
optimized for intact protein analysis. Spectra were acquired in linear TOF mode with a 
550 nsec delay in the m/z range from 25,000 to 75,000. Each spectrum was the sum of 
5000 single laser shots randomized over multiple positions within the same spot. 
Analysis of data was performed using FlexAnalysis and ClinProTools software (Bruker 
Daltonics Inc., Billerica, MA, USA). 
High Performance Liquid Chromatography 
Each HPLC run was performed in triplicate using a Hitachi Elite LaChrom system 
consisting of a L2130 pump, L-2200 auto sampler, and a L-2455 Fluorescent Detector.  
All the instruments were operated on the EZChrom Elite software.  All AGE species 
were separated on a Shodex (New York, NY, USA) RSpak C18 reverse phase HPLC 
column (5 μm×4.6 mm×150 mm) with a 415 Å pore size. Mobile phase A consisted of 
0.1% trifluoroacetic acid (TFA) and 1% acetonitrile (ACN) in water. Mobile phase B 
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included 0.1% TFA and 95% ACN in water. A linear gradient from 20% to 60% of 
mobile phase B was applied at a constant flow rate of 1.0 ml/min over 25 minutes. The 
formation of AGEs was monitored using a programmable fluorescence detector with 
excitation and emission wavelengths set at 340 nm and 430 nm, respectively. Prior to 
analysis, all solvents were degassed by sonication for 15 min and all samples were 
filtered by a 0.22 μm membrane.  
G.K. Peptide-Ribose Assay 
GK-peptide-ribose assay was performed with slight modifications from the 
previously published method (13). Briefly, GK peptide (40 mg/ml) was incubated with 
100 mM ribose in 100 mM sodium phosphate buffer, pH 7.0 and the testing compounds 
were added to the final concentrations of 0-300 μM.  After incubation for 6 h, the 
fluorescence of the mixture was read at 340 nm excitation wavelength and 420 nm 
emission wavelengths using a Spectra Max M2 spectrometer (Molecular Devices, 
Sunnyvale, CA, USA). 
Circular Dichroism Experiments 
The CD analysis was performed with Jasco J-720 spectropolarimeter (Tokyo, 
Japan) using quartz cuvettes with 1 mm path length. Interpretation of results was 
performed by the Spectra Manager software. Prior to spectral acquisition, the 
concentration of BSA in each sample was adjusted to 1 mg/ml with the 0.2 M phosphate 
buffer, pH 7.2. The CD spectral signatures were obtained in the far-ultraviolet region 
(200-250 nm) employing a total of 8 consecutive scans for each sample. The bandwidth 
in each case was adjusted to 1 nm.   
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 RESULTS  
Effects of Maple Gallotannins on the Protein Glycation (BSA-Fructose Assay) 
The inhibitory activities of maple gallotannins (GA, GB, GC, MF and MJ) against 
the formation of AGEs were shown in Figure 1.  The fluorescence of glycated BSA with 
the treatments of maple gallotannins were compared with the control group, where BSA 
was only incubated fructose.  When maple gallotannins were co-incubated with BSA and 
fructose complex, the fluorescence intensity significantly decreased in a concentration-
dependent manner.  As shown in table 1, ginnalin B and C inhibited 50% of AGEs 
formation at the concentration of 83.2 and 151.3 µM, respectively.  Ginnalin A had a 
comparatively lower IC50 value than the other ginnalin’s at 30.7 µM.  Maplexins F and J 
acted as the most potent anti-glycative agents with the IC50 value of 15.8 and 17.4 µM, 
respectively.  Meanwhile, all the maple gallotannins had superior inhibitory activities at a 
high concentration (300 µM) than AM as the positive control.  For instance, maplexin F 
inhibited 86.4 % formation of AGEs vs. AM of 38.6% inhibition. 
Maple Gallotannins Inhibited the AGEs Formation at the Early Stage 
The early stage products of the Maillard reaction of BSA with D-fructose were 
analyzed by using MALDI-TOF mass spectrometry (MALDI-TOFMS).  At this stage, D-
fructose reacted with the amino groups of an amino acid or a protein to form the Amadori 
products.  The numbers of sugar that were adducted to the BSA could be calculated based 
on the shifted mass of fructose-adducted BSA and natural BSA.  As shown in Table 2, in 
the absence of maple gallotannins, glycated BSA had a mass shift of 1580 Da indicating 
that 10 D-fructose were adducted to the BSA protein.  Maple gallotannins showed 
activities in preventing the adduction of fructose to protein.  Both GB and GC had less 
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mass shift (940 Da and 820 Da, respectively) and the number of adducted D-fructose 
reduced to 5.  In addition, the maplexin F treated BSA-D-fructose only had a increasing 
of 320 Da mass, which was equivalent to the mass of two fructose added to BSA.  
Among all the maple gallotannins, GA and MJ were the most active ones in the inhibition 
of Amadori products formation.  Only 1 D-fructose was able to be adducted to BSA in 
the presence of GA or MJ which lead to a mass addition of 140 Da. 
Maple Gallotannins Inhibited the AGEs Formation at the Early Stage 
The intermediate AGEs fragments could be detected by their intrinsic 
fluorescence using HPLC-FL chromatograph spectra.  Representative AGEs fragment 
HPLC-FL profiles are shown in Figure 7. The HPLC-FL chromatograph of native BSA 
that co-incubated with ribose showed several appreciable peaks indicating that BSA 
protein interacted with carbonyl compounds and their AGEs products were generated (as 
shown in Figure 7 A).  However, peak intensities of ginnalin A treated group were 
significantly reduced as shown in Figure 7 C.  All maple gallotannins were able to 
decrease the formation of AGEs as comparing with the control group (Figure 8) and the 
quantitative analysis of production of intermediate AGEs products are shown in Table 3.  
Maplexin J was the most active gallotannin that decreased the AGEs production to 4.6% 
followed by MF (7.2%). Other maple gallotannins, GC, GB and GA, also showed 
comparable inhibition percentage at 13.8%, 10.5% and 9.9%, respectively. 
Maple Gallotannins Inhibited the AGEs Formation at the Late Stage  
A synthetic peptide (G.K. peptide) containing a lysine residue was co-incubated 
with ribose in the presence or absence of maple gallotannins.  This assay was adopted to 
evaluate the inhibitory ability of maple gallotannins against the cross-linking of N-
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acetylglycyllysine methyl ester and ribose as in the late stage of AGEs formation.  The 
fluorescence of G.K. peptide-ribose that co-incubated with maple gallotannins during this 
protein glycation course were determined and compared with that of G.K. peptide-ribose 
alone as control.  The inhibitory activities of maple gallotannins were in a concentration-
dependent manner as shown in Figure 9 (A).  Although maple gallotannins merely 
showed inhibition of peptide-ribose cross-linking at 5 μM (inhibition rate < 20%), their 
activities clearly increased at 50 μM or higher concentrations.  For example, maplexin F, 
as the most active gallotannin, showed inhibition effects of 40.1, 50.2 and 57.9% at the 
concentrations of 50, 100 and 300 μM, respectively.  The inhibitory effects of maple 
gallotannins at the highest concentration (300 μM) are shown in Figure 9 (B).  Apart 
from maplexin F, all maple gallotannins at 300 μM nearly inhibited the half of peptide-
ribose glycation (ranged from 48.5 to 50.1%), whereas the positive control, 
aminoguanidine, only showed 6.8% inhibition.  Only at a much higher concentration of 5 
mM did Aminoguanidine show superior activity (63.1% inhibition) compared to the 
maple gallotannins. 
Conformational changes of BSA induced by AGEs 
The formation of AGEs often leads to the conformational changes of native 
protein.  In order to study if maple gallotannins were able to protect BSA protein by 
maintaining its secondary structures from AGEs formation, the CD spectra of glycated 
BSA and native BSA were obtained and compared with that of maple gallotannins treated 
BSA.  As shown in Figure 8, the CD spectra of glycated BSA protein clearly showed an 
alteration in the secondary structure as comparing with intact BSA protein, while maple 
gallotannins had the protective effects against the conformational changes.  Quantitative 
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analysis of the spectra (Table 4) demonstrated that maple gallotannins maintained BSA 
protein α-Helix structures in the order of MJ (67.7%) > MF (63.9%) > GA (59.3%) > GB 
(42.8%) > GC (40.2%), at a concentration of 100 μM. 
 
DISCUSSION AND CONCLUSSION 
 Maple gallotannins, which structurally feature different numbers and locations of 
galloyl groups attached to a glucitol moiety, demonstrated numerous bioactivities 
including anti-oxidant, anti-α-glucosidase and anti-cancer (14, 16, 17, 19).  Although 
maple species extracts have been studied for the anti-glycation property (20), maple 
gallotannins as pure compounds have not been evaluated for anti-AGEs effects, nor the 
mechanisms of inhibitory activity against AGEs formation have been elucidated.  
Therefore, we initiated this study to investigate the anti-AGEs effects of maple 
gallotannins at individual stages of AGEs formation.  In addition, the activities of mono-
galloyl gallotannins (ginnalins B and C), di-galloyl gallotannin (ginnalin A), tri-galloyl 
gallotannin (maplexin F) and tetra-galloyl gallotannin (maplexin J) were discussed in a 
SAR context. 
 All of the gallotannins displayed anti-AGEs effects in a concentration-dependent 
manner (Figure 2).  At the highest concentration (300 µM), tri-galloyl MF had the most 
potent inhibitory effect (86.3% inhibition) and tetra-galloyl MJ had a comparable activity 
as 81.7% inhibition.  Then the activity order was followed by di-galloyl gallotannin 
(GA), and GB/GC as mono-galloyl gallotannins.  It seemed that the inhibitory activities 
of maple gallotannins were enhanced as increasing the number of galloyl group on the 
glucitol.  Additionally, a minimum number of two-galloyl groups were critical for the 
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maple gallotannins to possess potent inhibitory effects.  This SAR observation was also 
further supported by the assays that evaluate the anti-AGEs activities at individual stage. 
 At the early stage of AGEs development, amino groups on lysine or arginine 
residue are able to condense with the carbonyl group of a reducing sugar by nucleophilic 
attack to form an unstable aldimine product (21).  Schiff base is reactive and can be 
further rearranged to produce a stable ketosamine product known as the Amadori 
products.  Many biophysical tools, such as MALDI-TOF-MS, are able to elucidate the 
adduction of reducing sugar to the amino groups of a protein (22, 23).  The number of 
adducted sugar to the BSA protein could be calculated based on the mass shift of the 
protein.  The MALDI-TOF-MS data revealed that GA, MF, and MJ were superior in the 
interruption of fructose-BSA protein adduction as comparing with mono-galloyl 
gallotannins (GB and GC) where only moderate activities were observed.  
 Reactive carbonyl species (RCS) are the driving force in the intermediate phase of 
AGEs formation.  The carbonyl compounds including glyoxal, 3-deoxyglycosone and 
methylglyoxal are generated in the early stage of AGEs formation.  Reactive dicarbonyl 
compounds further react with Amadori products fragments and generate the intermediate 
AGEs products with intrinsic fluorescence (24).  In this study, HPLC equipped with a 
fluorescent detector was able to characterize the RCS-BSA products by their fluorescent 
chromophores.  All maple gallotannins were active in the FL-HPLC assay indicating that 
the presence of maple gallotannin hindered the interaction of RCS and BSA protein.  
However, it is noteworthy that maple gallotannins were not able to trap methylglyoxal as 
the most active RCS (data not shown).  Therefore, maple gallotannins might inhibit the 
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formation of middle stage AGEs by impeding the catalysis of RCS generation, rather than 
directly trapping the generated carbonyl compounds. 
 In the last stage of AGEs formation, reactive RCS could further interact with 
Amadori products to generate a class of heterogeneous complex including fluorescent 
cross-linked structures.  The synthetic G.K. peptide with lysine residue is feasible to react 
with ribose to form the cross-linking products.  Therefore G.K. peptide-ribose system 
was adopted to mimic the late stage of AGEs development.  Although mono-galloyl 
gallotannins (GB and GC) were less active than GA, MF and MJ at low concentrations (5 
or 10 μM), all gallotannins demonstrated potent inhibitory activities at 300 μM.  Since 
oxidation stress is a pivotal factor in the late stage of AGEs formation, maple 
gallotannins, which have been reported as potent free radical scavengers, may serve as 
anti-oxidants to neutralize reactive oxygen species.  However, it needs further 
investigation to evaluate the free radical trapping capacities of maple gallotannins in the 
glycation course. 
 Lastly, it is known that the secondary structures are crucial in terms of maintain 
the protein function and studies have demonstrated that BSA protein loss it α-Helix 
conformation during protein glycation (25).  Our CD spectra confirmed that maple 
gallotannins were able to protect BSA protein by attenuated the conformational changes 
induced by fructose.  In addition, SAR effect was also in agreement with previous 
observed pattern.  
 In this study, maple gallotannins were evaluated for the anti-AGEs activity and 
their mechanisms of actions were studied by examining their inhibitory effects in the 
early, middle and late stage of AGEs formation.  All maple gallotannins displayed anti-
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AGEs formation effects by blocking the formation of intermediate Amadori products, and 
breaking the cross-linking of proteins.  Information obtained from this study is important 
for the utilization of maple species as potential anti-AGEs management. 
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FIGURE AND TABLE LEGEND 
Figure 1: Chemical structures of aminoguanidine, ginnalins A-C, maplexin F and 
maplexin J. 
Figure 2: Inhibitory effect of AM, GA, GB, GC, MF and MJ against the formation of 
AGEs. 10 mg/ml BSA and 100 mM D-fructose were incubated at 37 °C in 0.2 M 
phosphate buffer pH 7.4. Prior incubation, each sample was treated with different 
concentrations of natural products. Aminoguanidine (AM) was served as positive control. 
After incubating for 21 days, the formation of fluorescence AGEs in each solution was 
determined at excitation and emission wavelengths of 370 nm and 435 nm respectively. 
Each fluorescence reading was then compared to the intensity of negative control solution 
which incubated in the absence of natural products.  
Figure 3.1: MALDI-TOF mass spectrum of the +2 ion of A) BSA alone, B) BSA 
glycated with fructose for 3 days at 37 °C, C) BSA glycated with fructose in the presence 
of 100 µM GB for 3 days at 37 °C, and D) BSA glycated with fructose in the presence of 
100µM GC for 3 days at 37 °C.  
Figure 3.2: MALDI-TOF mass spectrum of the +2 ion of A) BSA alone, B) BSA 
glycated with fructose for 3 days at 37 °C, C) BSA glycated with fructose in the presence 
of 100 µM GA for 3 days at 37 °C, and D) BSA glycated with fructose in the presence of 
100 µM MJ for 3 days at 37 °C.  
Figure 3.3: MALDI-TOF mass spectrum of the +2 ion of A) BSA alone, B) BSA 
glycated with fructose for 3 days at 37 °C, C) BSA glycated with fructose in the presence 
of 100µM MF for 3 days at 37 °C.  
  70 
Figure 4: The shifted m/z value of glycated BSA and treatment group as comparing to 
the natural BSA.  Treatment group: AM, GB, GC, GA, MF and MJ, all the final 
concentration of each testing compound was 100 µM.  Blue bars indicate the calculated 
fructose that added to the BSA. 
Figure 5: HPLC-fluorescence elution profiles of 10 mg/ml BSA and 100 mM D-ribose 
after 7 days incubation at 37 °C with or without any treatment. Negative control solution 
consisted of BSA and D-ribose alone (A). Positive control sample consisted of BSA and 
D-ribose in the presence of 100 µM aminoguanidine (B). Experimental groups contained 
BSA, D-ribose and 100µM maple gallotannins (C). The HPLC elution profile of the 
blank solution containing BSA only yielded no fluorescence absorbing peaks suggesting 
the absence of AGE products in the blank sample after 7 days incubation (data not 
shown). Repeat chromatographic analysis of reaction mixtures by HPLC revealed no 
significant differences in the elution profiles of any of the AGE peaks in each of 
solutions.  
Figure 6: Fluorescence intensity of BSA and D-ribose complexes with absence and 
presence of maple gallotannins. 
Figure 7: (A) Inhibitory effects of maple gollotannins on the final stage of protein 
glucation (G.K. peptide-ribose assay).  G.K. peptide (40 mg/ml) was co-incubated with 
ribose (800 mM) for 9 hours in the absence and presence of maple gallotannins at 
concentrations from 5 to 300 µM.   Aminoguannidine (300 and 5000 µM) were served as 
positive controls.  (B) Inhibitory effects of maple gollotannins at 300 µM on the final 
stage of protein glycation (G.K. peptide-ribose assay).   Fluorescence of samples was 
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measured at excitation 340 nm and emission 420 nm and results are means ± SD for three 
independent tests. 
Figure 8: Far-UV circular dichroism spectra of native BSA, glycated BSA and maple 
gallotannins treated BSA protein.   
Table 1: Inhibitory effects of maple gallotannins on the formation of AGEs.  The 
activities were expressed in IC50 value and the inhibition rate of testing compounds at 300 
μM.  Aminoguanidine was served as the positive control. 
Table 2: The mass shift and possible number of adducted fructose of glycated BSA and 
maple gallotannins treated BSA protein. 
Table 3: The HPLC-FL area under curve value for middle stage AGEs products in the 
FL-HPLC assay. 
Table 4: Secondary structures (α-Helix and β-sheet) of native BSA, glycated BSA and 
maple gallotannins treated BSA protein.   
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Table 1: 
        
Compd. # of galloyls IC50 (μM) Inhibition % (at 300 μM) 
GB 1 83.2 ± 2.8 67.1 
GC 1 151.3 ± 3.4 58.1 
GA 2 30.7 ± 0.6 76.9 
MF 3 15.8 ± 1.1 86.3 
MJ 4 17.4 ± 0.9 81.7 
AG − > 300 38.6 
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 Table 2:  
 
  
    
Treatment  
m/z value of 
+2 ion (Da) 
m/z value of  
+1 Ion (Da) 
Shifted m/z 
value ( ΔDa) 
 
# of adducted 
D-fructose  
 
BSA 33,170  66,340  0 0 
BSA-Frc 33,960 67,920  +1580  10 
BSA-Frc + AG 33,960  67,920  +1580  10 
BSA-Frc + GB 33,640  67,280  +940  5 
BSA-Frc + GC 33,580  67,160  +820  5 
BSA-Frc + GA 33,240  66,480  +140  1 
BSA-Frc +MF 33,330  66,660  +320  2 
BSA-Frc +MJ 33,240  66,480  +140  1 
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Table 3:  
              
BSA 
treatment 
Peak 1 
Area 
Peak 2 
Area 
Peak 3 
Area 
Peak 4 
Area 
Total 
AGEs 
Area 
Relative 
AGE 
Area % 
Frc 57585823 11725137 23028179 2021731 94360870 100 
Frc + AG 54559011 9488533 24054288 1971908 90073740 95.456665 
Frc + GB 5188024 0 3166023 1568500 9922547 10.515531 
Frc + GC 6063848 1057314 4582415 1389647 13093224 13.875692 
Frc + GA 4154347 475608 1317708 853922 6801585 7.2080567 
Frc + MF 4494927 799368 2455755 1683915 9433965 9.9977512 
Frc + MJ 2022385 336914 1313660 432946 4105905 4.3512793 
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Table 4. 
                
Secondary 
structures 
natural 
BSA 
glycated 
BSA 
GB GC GA MF MJ 
α-Helix (%) 67.3 34.5 42.8 40.2 59.3 63.9 67.7 
β-Sheet (%) 7.7 21 15.1 16.5 10.2 9.4 9 
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Abstract: Our group has previously reported a series of bioactive gallotannins isolated 
from the red maple (Acer rubrum L.) species, namely ginnalins A-C and new molecules 
  87 
named maplexins A-I, with potent antioxidant capacities.  These natural compounds 
contain 1, 2 or 3 galloyl groups (from a possible 4 locations) attached to a 1,5-anhydro-D-
glucitol moiety. Herein, we initiated a project to investigate the cosmetic skin 
lightening/whitening applications of Maplifa
TM
, a proprietary extract from the leaves of 
the red maple species, in enzyme and cell based assays.  Maplifa
TM
 contains ca. 45-50% 
of ginnalin A along with other gallotannins including ginnalin B and C and maplexins.  
SAR studies showed that increasing the number of galloyl groups attached to the 1,5-
anhydro-D-glucitol moiety resulted in greater  inhibitory effects on tyrosinase enzyme. 
Consequently we synthesized maplexin J, the first tetragalloyl-glucitol (contains the 
maximum number of 4 galloyl groups) and confirmed our SAR observations.  Purified 
ginnalins A-C, as the representative gallotannins in Maplifa
TM
, were assayed for their 
inhibitory effects on melanin production in B16F10 cells.  Ginnalin A (contains 2 galloyl 
groups) clearly reduced the melanin content at 50 μM whereas ginnalin B and C (contains 
1 galloyl group of each) showed only minor anti-melanogenic effects.  Lastly, the 
mechanisms of the inhibitory effects of ginnalins A-C on melanogenesis in B16F10 cells 
were elucidated by using real-time PCR and Western blot experiments.  The results 
indicated that ginnalins were able to down-regulate the expression of MITF, TYR, TRP-1 
and TRP-2 gene levels in a time and dose-dependent manner and significantly reduce the 
protein expression of TRP-2 gene.  The findings in our study indicate that 
phytochemicals in red maple leaves possess anti-melanogenic effects and thus may have 
cosmetic skin-whitening applications. 
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Introduction 
In mammals, skin pigments are produced in the melanosomes of melanocytes 
cells that are situated on the basal layer between the dermis and epidermis.(1)  The 
pigmentation plays a crucial role in protecting skin against radiation-induced damage 
such as exposure to ultraviolet light.  However, overproduction or abnormal 
accumulation of melanin may lead to many skin hyperpigmentation disorders including 
freckles, age spots, post-inflammatory hyperpigmentation and even melanoma.(2)  
Undesired excessive skin pigmentation is a severe health concern since it can cause 
negative burdens on patients’ psychological well-being.  Thus, skin depigmentation 
remains a compelling research area for the cosmetic industry and the exploration of novel 
classes of safe and effective melanogenesis inhibitors from natural sources has attracted 
immense research interest.  
 The biosynthesis of melanin is collectively regulated by over 100 distinct genes. 
In mammals, three enzymes, tyrosinase (TYR), tryosinase-related protein-1 (TRP-1) and 
tryosinase-related protein-2 (TRP-2) are essential for the overall melanin production.(3)    
Tyrosinase performs a pivotal role in the modulation of melanogenesis.  It is the rate-
limiting enzyme that catalyzes the hydroxylation of L-tyrosine into 3,4-
dehydroxyphenylalanine (DOPA) and consequently oxidizes DOPA into DOPA 
quinone.(4)  TRP-2, which serves as a DOPA-chrome tautomerase (DCT), further 
promptly coverts DOPA quinone into 5,6-dihydroxyindol-2-carboxylic acid (DHICA), 
whereas TRP-1 facilitates the oxidization of DHICA to form carboxylated indole-
quinone.(5)  Two types of melanin are produced: a red/yellow pheomelanin and a 
black/brown eumelanin.  The TYR enzyme is critically involved in both pheomelanin and 
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eumelanin synthesis while TRP-1 and DCT contribute more in the synthesis of 
eumelanin.(6)  Microphthalmia-associated transcription factor (MITF) is a primary 
transcriptional activator of the melanogenic enzymes and seems to be the principle 
transcription regulator that mediates the survival, proliferation and differentiation of 
melanoblasts and melanocytes.(7)  Given that melanin synthesis in mammal involves 
multiple-step catalyzation   that modulated by a group of enzymes and transcription 
factors, it is important to understand the biological molecular mechanisms of 
melanogenesis inhibitors. 
 Although many synthetic compounds, such as hydroquinone and its derivatives 
had been conventionally used to suppress the over production of melanin, their 
application in cosmetics have been restrained because the lack of effectiveness or 
potential side effects including skin irritation and/or toxicity.(8, 9)   Therefore, natural 
products and botanical extracts have emerged as attractive candidates for melanogenesis 
inhibitory applications since they tend to be safe and have fewer adverse effects than 
synthetic compounds.   
The maple genus (Acer) comprises of over 120 species, most of which are found 
in Asia, with the remaining being native and endemic to North America.  Phytochemical 
and biological investigation of Acer species including A. buergerianum (China maple) 
and A. nikoense (Japanese maple) resulted in a number of compounds with anti-
melanogenic effects in B16F10 cells.(10, 11)  Interestingly, A. rubrum L. (red maple) 
which is native to eastern North America was traditionally used as a folk medicine by the 
Native Americans for many ailments including dermatological disorders.(12)   Moreover, 
a recent report supports the cosmetic potential of a red maple bark extract but neither the 
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active compounds nor the mechanisms of action have been identified.(13)   Furthermore, 
until now, the leaf extract from the red maple species have never been investigated for its 
cosmetic application, in particular relating to anti-melanogenic effects, nor have the 
active compounds therein been identified. 
For the past 5 years, our laboratory has been involved in a comprehensive 
phytochemical and biological program of studies on maple sap, maple syrup, and native 
North American maple plant parts, mainly the sugar maple and red maple species.  This 
work has resulted in the isolation and identification of over 100 compounds from maple, 
many of which are new molecules, with anti-oxidant, anti-α-glucosidase and anti-cancer 
activities.(14-18)  Here, we developed a proprietary standardized extract from red maple 
leaves and evaluated the cosmetic applications of the extract, and its major purified 
chemical constituents, for anti-tyrosinase and anti-melanogenic effects on B16F10 cells.  
 
Materials and methods 
Materials: Leaves of A. rubrum were collected on the University of Rhode Island (URI) 
Kingston campus, (RI, USA) by Mr. J. Peter Morgan.  A voucher specimen has been 
deposited in the URI College of Pharmacy Heber W. Youngken Jr. Greenhouse and 
Herbarium.  All solvents were of either ACS or HPLC grade and were purchased from 
Wilkem Scientific (Pawtucket, RI).  Mushroom tyrosinase, L-tyrosine, 4-hydroxyphenyl 
β-D-glucopyranoside (arbutin) and kojic acid were purchased from Sigma–Aldrich (St. 
Louis, MO). Ginnalins A-C and maplexins E were isolated from the red maple species as 
previously reported by our group.  Maplexin J, a new synthetic gallotannin analogue 
containing four galloyl groups on a 1,5-anhydro-D-glucitol moiety, was chemically 
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synthesized in our laboratory. Unless otherwise specified, all other chemicals were 
purchased from Sigma–Aldrich.  The HPLC analyses were performed on a Hitachi Elite 
LaChrom system consisting of a L2130 pump, L-2200 auto sampler, a L-2455 Diode 
Array Detector, and a Phenomenex Luna C18 column (250  10 mm, S-5 μm).  All the 
instruments were operated on the EZChrom Elite software. 
Preparation of Maplifa
TM
: Maplifa
TM 
was prepared by proprietary protocols developed 
in our laboratory.  Briefly, leaves of red maple were dried and macerated in aqueous 
ethanol to obtain the crude extract which was then further purified on a resin column to 
remove chlorophyll and other plant pigments.  Maplifa
TM
 was obtained as an off-white 
free flowing powder after solvent removal. 
Cell culture and treatment:  Murine melanoma B16F10 was purchased from the 
American Type Culture Collection (Rock-ville, MD).  Cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) medium (Wilkem Scientific, RI) that was 
supplemented with 10% v/v fetal bovine serum, 1% v/v nonessential amino acids and 1% 
v/v antibiotic solution at 37 °C in 5% CO2.(19)  Samples were dissolved at a 
concentration of 50 mg/mL in dimethylsulfoxide (DMSO) as stock solution and then 
diluted to the desired final concentrations with growth medium.  The final DMSO 
concentration was less than 0.1%. 
Tyrosinase inhibition assay:  Inhibitory effects of Maplifa
TM
, ginnalins A-C and 
maplexins F-J on mushroom tyrosinase were evaluated spectrophotometrically using L-
tyrosine as a substrate according to a method described previously with minor 
modification.(20)  Tyrosinase inhibition assays were performed in 96-well microplate 
format using SpectraMax M2 microplate reader (Molecular Devices, CA).  Briefly, 
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testing samples were dissolved in 10% DMSO at a concentration of 5.0 mg/mL and then 
diluted to different concentrations with phosphate buffer (0.1 M, pH 6.8).  Each well 
contained 40 μL of sample with 80 μL of phosphate buffer solution, 40 μL of tyrosinase 
(100 units/mL), and 40 μL L-tyrosine (2.5 mM). The mixture was incubated for 20 min at 
37 °C, and absorbance was measured at 490 nm. Each sample was accompanied by a 
blank containing all components except L-tyrosine. Kojic acid and arbutin were used as 
positive controls.  The results were compared with a control consisting of 10% DMSO in 
place of the sample. The percentage of tyrosinase inhibition was calculated as follows: 
[(ΔAcontrol − ΔAsample)/ ΔAcontrol] × 100 
Cell viability tests: The MTS assay was carried out as described previously with 
modiﬁcations.(17) At the end of either 24, 48 or 72 h of treatment with test samples (in 
the concentration range of 1-100 μM), 20 μL of the MTS reagent, in combination with 
the electron coupling agent, phenazine menthosulfate, were added to the wells and cells 
were incubated at 37 °C in a humidiﬁed incubator for 3 h. Absorbance at 490 nm was 
monitored with a spectrophotometer (SpectraMax M2, Molecular Devices Corp., 
operated by SoftmaxPro v.4.6 software, CA, USA) to obtain the number of cells relative 
to control populations. Inhibition of proliferation in the sample treatment cells are 
expressed as percentage compared to control (0.1% DMSO) cells. Data are presented as 
mean values ± S.D. and were obtained from three separate experiments. 
 Cellular melanin contents: The melanin content was determined using a modification 
of the method described by Yoon et al.(21)  Briefly, B16F10 cells (5 × 10
4
 cells/well) 
were first seeded in 24-well plates for 24 h and then medium was changed with new 
DMEM medium containing test samples of various concentrations.  After 72 h 
  93 
incubation, the cells were harvested through trypsinization and washed with phosphate-
buffered saline (PBS) twice.  Then cells were lyzed with 1 N NaOH containing 10% 
DMSO and heated at 80 °C for 1 h.  After samples cooled down to room temperature, the 
amount of melanin content was spectrophotometrically measured at 400 nm. 
Real-time quantitative PCR analysis of MITF, tyrosinase (TYR), TRP-1 and TRP-2 
expression: The B16F10 cells were planted in 6-well plates at a density of 2.0 × 10
5
 
cells/well.  After incubated for 24 h, cells were treated with 2 or 10 μM of ginnalins for 
48 or 72h.  Total RNA was isolated from cells using TRIzol reagent (Invitrogen) 
according to the manufacturer’s instructions. One microgram of total RNA was converted 
to single-stranded cDNA using oligo(dT)18 primers, and mRNA levels were quantified 
by quantitative real-time PCR using a Roche LightCycler detection system (Roche 
Applied Science, Mannheim, Germany). Samples were run by using SYBR Green and 
compared with levels of b2m rRNA as a reference housekeeping gene. Quantitative real-
time PCR conditions were optimized for each gene using appropriate forward and reverse 
primers. All oligonucleotides were synthesized by Invitrogen Inc., CA.(22) 
Evaluation of MITF, TYR, TRP-1 and TRP-2 expression expression by western blot:  
Expressions of melanin biosynthesis-related proteins, including MITF, TYR, TRP-1 and 
TRP-2 expression in B16F10 cells were measured by western blot.  After incubation with 
ginnalins for 72 h, proteins from cells were resolved by SDS-PAGE and then transferred 
to polyvinylidene ﬂuoride membrane. The membrane was blocked with 5% nonfat dry 
milk in Tris-buffered saline with Tween followed by incubation with primary antibodies 
overnight. Bands were visualized on X-ray ﬁlm using an ECL detection kit (Amersham 
Biosciences, Piscataway, NJ).(23) 
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Statistical analysis: Two-tailed unpaired student’s t-test was used for statistical analysis 
of the data using the Ofﬁce Excel 2010 software. A p value < 0.05 was considered 
signiﬁcant. 
 
 Results 
 Effects of ginnalins A-C on tyrosinase activity: Inhibitory effects of five maple 
gallotannins, ginnalins A-C (1-3) and maplexin F and J (4-5), on mushroom tyrosinase 
activity were assayed and their IC50 values are shown in Table 1. The gallotannins with 
two to four galloyl groups were more active than acertanins with only one galloyl group.  
Ginnalin A (1), a 1,5-anhydro-D-glucitol moiety with two galloyl groups, showed the high 
inhibitory activity with an IC50 value of 181.9 μM.  Similarly, maplexin F (4) and 
maplexin J (5), with three or four galloyl groups respectively, showed comparable IC50 
values of 212.2 and 190.4 μM.  However, gallotannins with only one galloyl group, 
namely, ginnalin B (2) and ginnalin C (3), only showed weak inhibitory effects ( IC50 = 
1047.3 and 857.8 μM, respectively) on the tyrosinase enzyme.   
Cell viability of ginnalins A-C on B16F10 cells: To further investigate the anti-
melanogenic activities of ginnalins A-C, present in the Maplifa
TM
 extract, cellular based 
assay were employed to measure the melanin content on murine melanoma B16F10 cells.  
In order to determine the non-toxic concentrations of ginnalins for cellular assays, cell 
viability on B16F10 cells were first evaluated by using MTS assay.  Melanoma B16F10 
cells were treated with serial concentrations (0, 5, 10, 25, and 50 μM) of ginnalins A-C 
for 72 h and the cell viabilities were determined by comparing with the untreated control 
group.  All of the ginnalins B and C were non-toxic to B16F10 cells at all concentrations 
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from 0 to 50 μM (cell viabilities > 90%), while, ginnalin A was non-toxic at low 
concentrations (5 and 10 μM) but slightly reduced the B16F10 cell viabilities to 87.0% 
and 89.5% at concentrations of 25 and 50 μM, respectively.  According to findings from 
previous studies that screens for safe and effective melanogenesis inhibitors in cell based 
assays, 40 μg/mL is a threshold concentration for cellular melanogenesis assays.  Thus, 
all of the test concentrations of the ginnalins in our study were lower than this published 
threshold and, and therefore can be considered as being non-toxic doses resulting in safe 
melanogenesis inhibitory agents. 
Effect of ginnalins A-C on melanin contents: The contents of biosynthesized melanin in 
melanoma B16F10 cells that treated with ginnalins A-C at serial concentrations were 
evaluated by comparing with the control group.  Although ginnalins did not show 
significant inhibitory activities on melanin biosynthesis at low concentrations (5 and 10 
μM), ginnalin A demonstrated reduced the formation of melanin at relatively high 
dosages.  The melanin contents in B16F10 that treated with 25 and 50 μM of ginnalin A 
clearly decreased to 79.1% and 56.7%, respectively, compared to those of in control 
group, while, ginnalin C slightly reduced melanin level to 89.7% and 68.8% at 25 and 50 
μM, respectively.  In addition, cells treated with 25 and 50 μM of ginnalin B remained 
melanin level at 90.0% comparing with the control group. 
Effect of ginnalins A-C on tyrosinase-related gene and protein expression: Melanin 
biosynthesis involves multi-step pathways.  In order to determine the molecular 
mechanisms of inhibitory effects of ginnalins on melanin synthesis, expression levels of 
melanogenesis related genes, including MITF, TYR, TRP-1 and TRP-2, in B16F10 cells 
were analyzed by using RT-PCR.  As shown in Fig. 5, after treated with 10 μM of 
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ginnalin A for 48 h or 72 h, the mRNA expressions of MITF, TYR, TRP-1 and TRP-2 
were significantly reduced. Although ginnalin B only slightly decreased the TYR 
expression by 10.0 and 7.5% at 48 and 72 hours, it significantly decreased the mRNA 
expressions of MITF, TRP-1 and TRP-2 at 48 and 72 hours.  In addition, ginnalin C did 
not reduce the TRP-1expression level at all time points and only slightly decreased TYR 
and TRP-2 expression, however, it significantly down-regulated the mRNA expression of 
MITF at 48 and 72 hours. 
 Furthermore, the regulation of ginnalins on the protein expressions of 
melanogenesis related enzymes in B16F10 cells were evaluated by using Western blot.  
Ginnalins did not show down-regulation effects on the protein expression of melanin 
biosynthesis related enzymes at 5 and 10 μM at 48 hours, nor reduce the expressions of 
these proteins in B16F10 cells that co-incubated with ginnalins for 72 hours.  However, 
in the melanoma cells that treated with 10 μM of ginnalins A-C for 72 hours, the protein 
expression of TRP-2 were decrease by 87.9, 92.0, and 69.5% by ginnalins A-C, 
respectively (Fig. 6.). 
Discussion and conclusion 
 Previous studies have revealed that a number of maple (Acer species) extracts 
possessed many biological activities including anti-oxidant, anti-microbial, anti-
angiogenic and anti-melanogenic.(10, 11)  Some maple species that are indigenous to 
Asia including China maple (Acer buergerianum) and Japanese maple (Acer nikoense), 
have been reported for their inhibitory effects against melanogenesis on B16 cells and 
potentials for cosmeceutical applications.  Since these bioactivities were largely 
associated with the phenolic content in the maple extracts, it was suggested that anti-
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oxidant capacity of maple polyphenols was critical for the aim of developing maple 
extracts for the medicinal and/or nutritional uses.(24)  In addition, standardization of 
maple extracts is another crucial factor for the application of maple extracts.  Although 
tested maple extracts were mainly obtained from organic solvents extraction, an efficient, 
environmentally and economically friendly extraction approach is needed to produce 
maple extracts in consistent quality.  Therefore, our laboratory previously developed 
Maplifa
TM
 as a standardized extract from red maple leaves and we herein present the 
biological evaluation of major polyphenolic components of Maplifa
TM
, namely ginnalins 
A-C, for the potential skin-whitening uses.   
Ginnalin A, as the predominant phenolic in the Maplifa
TM
 extract, has been 
known as a strong antioxidant for the free radical trapping capacity.(14)  Furthermore, 
ginnalin A has two galloyl groups that attached to the 1,5-anhydro-D-glucitol while  both 
ginnalin B and C only has one galloyl on the same sugar core.  Therefore, ginnalins A-C 
as represent compounds of Maplifa
TM
 were chosen for the further biological assays and 
possible structure and activity relationship were discussed.  Our in vitro study showed 
that ginnalins A-C, maplexins F and J had moderate inhibitory effects against tyrosinase.  
Generally, the inhibitory activity of gallotannins (GA, MF and MJ) with multiple galloyl 
group (n>2) were greater than mono- galloyl substituted ginnalins (B and C).  However, 
glucitol moiety with two or more galloyl groups had comparable activity.  This 
phenomenon suggests that maple gallotannins may directly bind to tyrosinase and hinder 
the formation of active site.  In addition, more galloyl groups on the glucitol showed 
stronger inhibition potentially by increasing the chance of the ginnalins bind to tyrosinase 
to form hydrogen bonds which may stabilize the ligands-enzyme complex.   
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In order to further explore the anti-melanogenic property of ginnalins, cellular 
based assays were employed on the B16F10 murine melanoma cells.  Firstly, the cell 
viability was accessed by using MTS assay to obtain a safe range of ginnalins 
concentrations for the further experiments.  Since anti-melanogenic activity of ginnalins 
on B16F10 cells should be assayed at the concentrations without inducing significant 
cytotoxicity, the threshold concentration was set to 50 μM for all testing compounds.  
This concentration is lower 40 μg/mL (equivalent to 85 μM of ginnalin A or 126 μM of 
ginnalin B/C) as a general concentration limit for cellular based anti-melanogenesis 
assay.  All ginnalins had cell viability over 90% indicating that ginnalins were non-toxic 
to the cells.  In the melanin content assay, ginnalins A-C all showed a concentration 
dependant manner in the inhibition of the melanin biosynthesis in B16F10 cells.  Similar 
SAR effects were observed as in the tyrosinase assay, ginnalin A was more potent than 
other two ginnalins at down-regulating melanin biosynthesis.   This activity was 
supported by examining the mRNA expression of genes that regulate melanin production.  
The RT-PCR assay demonstrated that in 48 or 72 hours treatments, ginnalin A was the 
most potent one to decrease the mRNA expression of MITF, TYR, TRP-1 and TRP-2.  It 
had a significant decrease of MITF expression comparing to other melanin synthesis 
genes indicating that ginnalin A down-regulating melanin biosynthesis by suppression of 
transcriptional activator of melanin production related enzymes at the mRNA 
transcriptional level.  Lastly, Western blot assay was applied to measure the protein 
expression of genes MITF, TYR, TRP-1 and TRP-2.  A decreased expression level of 
TRP-2 suggested that ginnalins were able to impede the transformation of DOPA quinone 
into 5,6-dihydroxyindol-2-carboxylic acid which could further be oxidized to form the 
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melanin pigments.  The RT-PCR and Western blot assays provided useful information 
towards the molecular inhibitory mechanisms of ginnalins against melanogenesis. 
Our finding suggested that ginnalins A-C as the major phytochemicals in 
Maplifa
TM
 could individually reduce the production of melanin in B16F10 cells.  
However, it is possible that the polyphenols in the Maplifa
TM
 extract could inhibit the 
melanin formation in a synergistic manner, especially considering that the biosynthesis of 
melanin involves with multiple biochemical transformation and is under the regulation of 
numerous enzymes.  Therefore, Maplifa
TM
 might be developed as a novel skin-whitening 
agent or therapeutic strategy for the treatment of hyperpigmentation.  However, the 
efficacy and safety of Maplifa
TM
 need to be studied in the animal models. 
 
Figure and table legends 
Figure 1: Chemical structures of ginnalins A-C (1-3) and maplexins F (4) and J (5)  
Figure 2: HPLC-UV chromatograms of Maplifa
TM
, an ginnalin A-riched extract, 
showing the presence of ginnalins A–C (1-3) in the MaplifaTM extract. 
Figure 3: Effect of ginnalins A-C (1-3) on viability of B16F10 cells.  After 72 hours of 
treatment of serial concentrations (2-50 μM) of ginnalins (1-3), the viability of melanoma 
B16F10 cells were determined by MTS assay. Each value is presented as mean ± S.D. 
from triplicate independent experiments. 
Figure 4: Inhibition of cellular melannin content in B16F10 cells by ginnalins A-C.  
Cells were treat with of ginnalins A-C for 12 h, and the melanin content were compared 
to the control group.  Each value is presented as mean ± S.D. fro triplicate independent 
experiments. 
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Figure 5: The mRNA expression of MITF, TYR, TRP-1 and TRP-2 in ginnalins-treated 
B16F0 cells. Cells were treated with or without 10μM of ginnalins for 48 h (A) and 72 h 
(B). 
Figure 6: The expression of melanogenesis related protein MITF and TRP-2 in 
ginnalins-treated B16F0 cells. Cells were treated with or without 10μM of ginnalins for 
72 h and protein expression of MITF and TRP-2 were analyzed by Western blotting. 
Table 1: Inhibitory activity (IC50) of five phenolics, ginnalins A-C (1-3) and maplexins 
F-J (4-5), on tyrosinase enzyme.  
a
IC50 are presented as mean ± S.D. from triplicate 
independent experiments. *Positive controls. 
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Table 1:  
   Compd. # of galloyl group IC50 (μM)
a
 
1 2 181.9 ± 3.5 
2 1 1047.3 ± 2.7 
3 1 857.8 ± 6.9 
4 3 212.2 ± 5.5 
5 4 190.4 ± 1.7 
Kojic acid
*
 − 21.4 ± 0.1 
Arbutin
*
 − 63.0 ± 0.3 
 
 
 
 
 
 
